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Abstract 
Cetinkaya, C. 2005. Control of growth and differentiation of human neuronal and 
hematopoietic tumour cells via Myc/Max/Mad-network proteins  
Doctor’s dissertation 
ISSN 1652-6880, ISBN 91-576-7021-8 
 
The Myc/Max/Mad transcription factor network regulates a large number of genes involved 
in cell growth, differentiation and apoptosis. Myc activates and Mad represses and 
overlapping set of growth-promoting genes, and the network therefore seems to act as a 
molecular switch between growth and differentiation. Deregulation of myc–family genes 
occurs frequently in human cancers and is often associated with poor prognosis.  
  One aim of this thesis was to identify negative growth signals affecting the expression 
and/or activity of N-Myc- and Mad-family in neuroblastomas. Our results show that Mad1 
was upregulated during phorbol ester (TPA)-induced neuronal differentiation of SH-SY5Y 
human neuroblastoma cells lacking N-myc amplification, whereas this response was largely 
inhibited in N-myc-amplified neuroblastoma cells. However, interferon-γ (IFN-γ) in 
combination with retinoic acid (RA) or TPA strongly enhanced differentiation and growth 
arrest in the latter.  This was accompanied by reduced N-Myc and/or upregulated Mad1 
expression, resulting in changed occupancy at the ODC target gene promoter in vivo 
towards Mad1/Max predominance, and repression of N-Myc/Mad1 target genes. This 
suggests that combined RA+IFN-γ “differentiation therapy” may potentially be of clinical 
interest in neuroblastoma treatment. 
  Addressing the role of Mad1 during hematopoietic differentiation, we show that enforced 
Mad1 expression in U-937 monoblasts by an inducible expression system led to inhibited 
cell growth and proliferation. However, Mad1 did not induce or enhance differentiation in 
the absence or presence of differentiation signals. Surprisingly, Mad1 stimulated TNF-α-, 
but not Fas-induced apoptosis in U-937 cells.  
  Finally, addressing the still unclear mechanism by which c-Myc represses transcription, 
our results showed that differentiation-induced transcription of the cyclin-dependent kinase 
inhibitor  p21
Cip1 gene was repressed by c-Myc through interaction with the Zn-finger 
protein Miz-1 in vivo at the p21 core promoter. c-Myc seems to switch Miz-1 function from 
an activator to a repressor, thereby inhibiting cell cycle exit and differentiation. 
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Abbreviations 
bHLHZip   basic/helix-loop-helix/leucine zipper 
Cdk       cyclin  dependent  kinase 
ChIP     chromatin  immunoprecipitation 
CKI    cyclin  dependent  kinase  inhibitor 
CoIP     coimmunoprecipitation 
CTD     carboxy  terminal  domain 
GTF       General  transcription  factors 
HDAC    histone  deacetylase 
HAT     histone  acetyltransferase 
IFNγ     interferon-gamma 
Inr      initiator 
MB      Myc  box 
MIZ-1      Myc interacting zinc-finger protein 
NB      Neuroblastoma 
ODC     ornithine  decarboxylase 
PKC     protein  kinase  C 
pRb      Retinoblastoma  protein 
RA      retinoic  acid 
SID      Sin3  interaction  domain 
TAD     transactivation  domain 
TAF    TBP  associated  factor 
TBP    TATA  binding  protein 
TERT     Telomerase  reverse  transcriptase 
T P A     1 2 - O-tetradecanoylphorbol-13-acetate 
TRRAP    Transformation/Transcription  domain-associated  protein 
VITD3    Vitamin  D3 
 
 
 
 
 
 
 
 
 
 
 Background 
Development of Cancer 
Cancer is a genetic disease that evolves through multiple genetic alterations (for 
review see (Hanahan and Weinberg, 2000)). Extensive research during last 
decades has broadened our knowledge of molecular mechanisms involved in the 
process of tumour formation. But a complete picture of the cancer development is 
still missing.  
Alterations in three types of gene families are believed to be responsible for the 
generation of cancer: proto-oncogenes, tumour-suppressor genes and stability 
genes (for review see (Vogelstein and Kinzler, 2004)). Proto-oncogenes, which 
normally function to promote cell growth or survival, can contribute to tumour 
formation when mutated or expressed at abnormal high levels. Tumour suppressor 
genes, on the other hand are genes whose functional absence can lead to cancer. 
Carcinogenic mutations in such genes may result in inactive gene or gene product, 
which are then unable to inhibit cell growth. The stability genes (or caretakers), is 
a class of genes that include genes responsible for DNA repair. When stability 
genes are inactivated, mutations in other genes occur at a higher rate and genetic 
changes can not be kept to a minimum. 
A single mutation is not sufficient to transform a normal mammalian cell to a 
cancer cell since there are safeguard mechanisms existing. The ability to transform 
differs fundamentally between cells of different mammalian species. For example, 
cultured rodent cells require at least two genetic alterations while human cells 
require at least three (Hahn et al., 1999). But which genetic changes are needed for 
a normal cell to become a malignant cell? A cell possesses multiple control 
mechanisms. Circumvention or disruption of these control systems, leading to 
growth advantages, is always involved in tumour development.  These genetic 
changes include self-sufficiency in growth signals, insensitivity to antigrowth 
signals, block of differentiation, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, tissue invasion and metastasis and genomic 
instability (Hanahan and Weinberg, 2000). These processes will be described 
briefly below (summarised in figure 1). 
Cancer
Growth signal
autonomy
Resistance towards
apoptosis
Circumvention of
mortality barrier Induction of 
angiogenesis
Metastasis
Insensitivity to
antigrowth signals
Block of
differentiation
Genetic
instability
Figure 1: Outline of cellular processes affected by genetic alterations in cancer cells 
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  Normal cells need mitogenic signals to proliferate, signals that are usually 
supplied by neighbouring tissues. Transmission of these signals into the cell 
occurs through signalling molecules that bind to specific transmembrane receptors. 
Diffusible growth factors, extracellular matrix molecules, and cell-to cell 
adhesion/interaction molecules are the signalling molecules. In contrast to normal 
cells, tumour cells grow in absence of mitogenic signals. Many of the oncogenes 
involved in cancer mimic normal growth signalling and thereby reduce their 
dependence on stimulation from their microenvironment. Independence of 
mitogenic signals can be achieved in different ways. One way is the autocrine 
stimulation there cancer cells produce their own growth factors. Mutations that 
activate transmembrane receptors leading to signalling in the absence of ligand or 
making the receptors hypersensitive, is another way (Slamon et al., 1987).  A 
possible mechanism is also the ability of cancer cells to switch the types of 
extracellular matrix receptors (integrins) they express, a switch that favours 
receptors that transmit progrowth signals (Giancotti and Ruoslahti, 1999, 
Lukashev and Werb, 1998). Both growth factors and matrix components can 
activate SOS-Ras-Raf_MAP kinase pathways (Aplin et al., 1998, Giancotti and 
Ruoslahti, 1999). A more complicated mechanism of acquired growth signal 
autonomy derives from changes in components of the downstream circuitry that 
receives signals from ligand-activated growth receptors and integrins. The SOS-
Ras-Raf_MAP kinase pathway plays a central and important role here. In many 
cancers, approximately in 25% of all human cancers, Ras proteins are altered 
structurally (Medema and Bos, 1993) and activated Ras contributes to several 
aspects of malignant phenotype (Shields et al., 2000). Tumors can also influence 
adjacent cells, like fibroblasts or immune cells, to produce growth signals.  
 
  In a normal cell, multiple antiproliferative signals operate together to limit cell 
proliferation and maintain tissue homeostatis. These signals can block 
proliferation either by forcing cells out of the active proliferative cycle into the 
quiescent (G0) state or by inducing cells into a postmitotic state, usually 
differentiation.   Insensitivity to such antigrowth signals is a common genetic 
alteration for cancer cells.  Examples of such antigrowth signals are the cytokines 
interferons (IFN-α, -β and -γ) and transforming growth factor- β (TGF-β). IFNs 
comprise a family of secreted proteins that bind to specific receptors on the 
surface of target cells, and they induce activation of gene transcription that 
negatively controls cell growth. IFNs signal through the Jak-Stat pathway, 
involving activation of members of the Janus
 family of kinases (JAKs) and the 
signal transducers and activators of transcription (STATs), (Brivanlou and 
Darnell, 2002).  TGF-β blocks progression through G1-phase of the cell cycle. 
Components of the TGF-β signalling pathway, such as Smads (Smad2, Smad4), 
are frequently mutated in several forms of cancer, (for review see, (Shi and 
Massague, 2003, ten Dijke and Hill, 2004).
Many antiproliferative signals are associated with the cell cycle clock, specifically 
the components involved in G1 phase transition (for a recent review see 
(Massague, 2004)).  Many, if not all, antigrowth signals are canalized through the 
tumour suppressor protein and cell cycle regulatory factor retinoblastoma (pRb). 
Most human tumours have mutations that deregulate or inactivate the function of 
pRb or other proteins involved in the regulation of Rb activity (Sherr, 2004).   11 
Another tumour suppressor gene whose inactivation is implicated in a high 
percentage of human cancer is p53. In response to various types of stress, p53 
becomes activated. As a consequence of this activation, cells can undergo 
increased DNA repair, senescence and apoptosis (Sherr, 2004).  
 
  Cell proliferation depends on more than avoidance of antiproliferative signals. 
Normal tissues also restrict cell proliferation by instructing cells to enter 
differentiated states by diverse mechanisms. Tumour cells use various strategies to 
avoid normal differentiation (for review see (Tenen, 2003)). Block of cellular 
differentiation is particularly evident among hematopoietic tumours. One strategy 
to avoid differentiation involves disruption of specific transcription factors that 
have crucial roles in the differentiation process. Translocations and deregulation of 
these transcription factors are seen, for instance, in leukaemia. Additionally, 
overexpression of many oncogenes can also block differentiation. For example, 
the c-Myc oncoprotein can induce a shift from differentiation to proliferation 
when overexpressed, (for review see (Oster et al., 2002)) 
 
  Another safe-guarding mechanism that normal cells have and that tumour cells 
need to block is apoptosis, the programmed cell death. An imbalance in normal 
cells, such as DNA damage, overexpression of oncogene, hypoxia or absence of 
survival factors, can trigger apoptosis. Many tumours suffer massive apoptotic cell 
death at early stages of the development due to these reasons. Therefore it is 
crucial for tumour cells to develop resistance against apoptosis (for recent review 
see (Lowe et al., 2004)). The most frequent strategy is the loss of pro-apoptotic 
tumour suppressor gene p53. Enhancement of survival molecules is another 
possible mechanism. Apoptosis, which is an energy dependent process, is 
performed and regulated by a large group of molecules, including surface 
receptors (such as the death receptor Fas), mitochondria associated molecules of 
the bcl-2 family, and caspases. All these molecules can be targeted when cancer 
cells develop strategies to avoid apoptosis. The Bcl-2 family proteins exhibit both 
pro-apoptotic (Bcl-2, Bcl-xl and Bcl-x) and anti-apoptotic (Bax, Bak, Bid and Bin) 
characteristics. Overexpression of Bcl-2 occurs in many tumours (e.g B-cell 
lymphoma, B-cell leukemia) and leads to inhibition of apoptosis. Upregulation of 
Bax by p53 activation, on the other hand, can elicit apoptosis. Caspases, that are a 
group of cysteine proteases and one of the main effectors of apoptosis, can be 
activated by death receptors such as Fas, (so called extrinsic pathway) or directly 
by cytocrome C release from mitochondria (so called intrinsic pathway). These 
proteins initiate and amplify various death signals and breakdown or cleave key 
cellular substrates that are required for normal cellular function, (Igney and 
Krammer, 2002, Okada and Mak, 2004). Despite the key role of caspases in 
programmed cell death, caspase mutations have been identified at low frequency 
in some tumors (e.g. colorectal cancer or head and neck carcinoma). Instead, 
caspases are frequently inactivated by epigenetic mechanisms (Hopkins-
Donaldson et al., 2003).  
 
  Maintaining the stability of the genome is critical to normal cell growth and 
development. DNA monitoring systems, check points (especially in mitosis), and 
repair enzymes ensure that mutations are rare. Even if mutation of a specific gene 
is not enough to cause cancer, cancers do yet appear. Genomes of tumour cells   12
must acquire increased mutation rates for tumours to progress (Loeb, 1991). 
Malfunction of the existing ¨caretaker¨ systems is believed to be involved in this 
increased mutability. Genetic alterations accumulated in tumour cells that have 
impact on genetic instability can include (Lengauer et al., 1998): chromosome 
losses, gains and translocations, such as 8:14 translocation in Burkitt’s lymphomas 
involving c-myc oncogene, amplification of certain genes, e.g myc gene 
amplification in neuroblastomas (Oster et al., 2002), inactivation of DNA 
mismatch repair genes, such as msh2 or mlhl (Cahill et al., 1999), loss of normal 
mitotic checkpoint pathways (Cahill et al., 1998) and disabled p53 pathways 
(Zhivotovsky and Kroemer, 2004).  
 
  Normal mammalian cells have limited replicative capacity (Hayflick, 1997), that 
enforce them stop dividing after a certain number of divisions (approximately 50) 
and enter a specific quiescent state called senescence.  This is due to shortening of 
the telomeres, the repetitive DNA-sequences and associated proteins protecting the 
ends of chromosomes. Telomerase, the enzyme maintaining the length of 
telomeres, is upregulated in malignant cells which add telomeres to the end of 
chromosomes after each division and makes cells avoid senescence. Most cancer 
cells maintain their telomere length by high expression of telomerase (85%–90% 
of cases), but there is also another mechanism, called alternative lengthening of 
telomeres (ALT) existing (Cech, 2004).  
 
  Both normal and tumour cells require oxygen and nutrients to survive and grow. 
Cells can only survive within a certain distance from a capillary.  Normally, cells 
do not have the ability to initiate and induce blood vessel formation, a process 
called angiogenesis. Therefore a tumour cell has to develop angiogenic abilities in 
order for tumour to grow and expand (Bouck et al., 1996, Hanahan and Folkman, 
1996). Activation of angiogenic inducers, such as vascular endothelial growth 
factor (VEGF) is common in many tumours (Ferrara, 2002).  
 
  Another hallmark of cancer is the ability of tumour cells to expand to 
neighbouring tissues or invade distant organs, a process named metastasis. 
Majority (90%) of human cancer deaths are caused by metastasis (Sporn, 
1996).The mechanism underlying invasion and metastasis is complex and poorly 
understood. Proteins that regulate cell-cell and cell-matrix interactions seem to 
play a central role. For instance, the expression pattern of integrin can be switched 
and the function of E-cadherin is lost in many invasive epithelial cancers 
(Cavallaro and Christofori, 2004). Downregulation or removal of proteins acting 
as suppressor of invasion and metastasis are also among observed processes 
(Hanahan and Weinberg, 2000).   
 
The Eukaryotic Cell Cycle 
The most fundamental property of a living organism is its ability to reproduce 
itself in order to grow and develop. This property is based upon the aspect that 
cells are able to duplicate by a highly ordered process known as the cell cycle. The 
cell cycle traditionally is divided into four phases, namely gap 1 (G1), DNA-
synthesis (S), gap 2 and mitosis (M), (see fig 2) (Johnson and Walker, 1999).  
 Fig.2: Overview of the mammalian cell cycle with emphasis on G1/S transition 
 
During G1 phase, cells grow in size, prepare for the process of DNA replication 
and are receptive to extracellular signals, which may trigger a commitment to 
entering the next phase of the cell cycle or exiting it. It has been shown, both in 
yeast and mammalian cells, that there are several points in the cell cycle called 
checkpoints, at which the cell cycle can be arrested if previous events have not 
been completed. Late in G1, at the G1 checkpoint, cells become committed to 
DNA replication and entering the next phase. Previous to the checkpoint, a cell 
will stop growing if soluble growth factors are removed from the surrounding 
fluid. However, subsequent the checkpoint cells will continue to progress through 
the remainder of the cell cycle regardless of presence of growth factors. DNA 
synthesis occurs in S phase while in G2 the cell prepares for the chromosome 
segregation and cell division. The checkpoint in G2 ensures that DNA is 
completely replicated, the cell is big enough and the environment is favourable. At 
this stage, mitosis is prevented until the cell complete all of the steps required for 
division. For instance, if DNA is damaged DNA repair system can be activated 
during this time of period. During M phase the cell physically divides into two 
separate daughter cells and an additional checkpoint here makes sure that the 
chromosomes are attached correctly to the spindle. After going through mitosis, a 
normal cell that re-enters G1 can either start cycling again or exit the cell cycle 
and enter a resting state called G0. Cells may stay in this quiescent state for days, 
weeks, or years, until they get signals indicating that it is time to divide again 
(Johnson and Walker, 1999). 
 
  Cell cycle progression is regulated by two families of proteins, the cyclin 
dependent kinases (Cdk:s) and cyclins. In higher eukaryotes nine Cdks and at least 
16 cyclins have been identified (Johnson and Walker, 1999). Cdks are a family of 
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serine/threonine kinases that control phosphorylation of several substrates, 
including the tumour suppressor protein Rb (pRb). Association with a cyclin at 
specific regulatory subunit called the cyclin box is required for the Cdk to be 
active. All cyclins contain this common homologous region. For full Cdk 
activation phosphorylation of a conserved Cdk threonine residue and 
dephosphorylations on some tyrosine residues are also needed. This 
phosphorylation is carried out by a Cdk-activating kinase (CAK) and the 
phosphate is removed by the Cdk-associated phosphatase (cdc25). Each cell cycle 
phase has its own distinct cyclin-Cdk combination.  For instance in mammalians, 
cyclins D and E in complex with Cdk 4/6 and Cdk2 are active during G1 whereas 
cyclins A and B in association with Cdk1 in G2/M phases (Arellano and Moreno, 
1997, Nigg, 1995).  
 
  One of the most important tasks for cyclin-Cdk complexes in G1 is ensuring 
G1/S transition by inactivating the retinoblastoma protein (pRb). The active 
unphosphorylated form of pRb arrests cells at the check point in late G1 phase of 
the cell cycle. This function of pRb, at least partly, depends on interactions with 
E2F family transcription factors (Harbour and Dean, 2000). It is suggested that the 
ability of pRb to arrest cells in G1 is mainly due to repression of E2F target genes 
important for cell cycle entry. The repression by Rb/E2F complex is partly 
dependent on the requirement of histone deacetylases (HDACs) (Magnaghi-Jaulin 
et al., 2000). Phoshorylation of Rb by Cyclin-Cdk complexes disrupt the 
interaction between Rb and E2F and transforms E2F from a repressor to an 
activator that allows transcription of E2F target genes necessary for completion of 
the cell cycle.  
 
  The first cyclin-Cdk complex, that is induced in response to mitogenic signals 
and activated during the G1-phase, is composed of a D-type cyclin (CycD1, D2 
and D3) in association with Cdk4 or Cdk6 depending on cell type (Sherr, 1995). 
The cyclin D dependent kinases phoshorylate pRb and thereafter the cyclinE/Cdk2 
complexes become active and complete the phoshorylation. E2F is released from 
pRb which in turn allows activation of the transcription of E2F target genes 
involved in DNA replication (Sherr and Roberts, 1999). Cyclin E and A, that are 
necessary for the G1/S transition are among these genes. CyclinE/Cdk2 is 
involved in maintaining pRb in the hyperphosphorylated state and as a 
consequence participates in a positive feedback loop. An additional function of 
CyclinD/Cdk4 complexes is to sequester Cdk inbitors (CKI) p21 and p27. By 
doing this CyclinD/Cdk2 makes it possible for CylinE/Cdk2 to reduce restriction 
by CKIs and facilitate its activation. When cells enter S phase, cyclin E is 
degraded and Cdk2 then associates with cyclin A. Cyclin A associated kinase 
activity (Cdk2 and in late S phase Cdk1) is necessary for entry into S phase, 
completion of S phase and entry into M phase. Some members of E2F are 
negatively regulated by cyclin A creating a negative feedback loop. Eventually, 
cyclin A and the B-type cyclins associate with Cdk1 to promote entry into mitosis. 
To exit mitosis, cyclin B destruction is required.  
 
  There are several different ways to regulate Cdks. Beside the positive regulation 
by cyclins, and multiple phosphorylations and dephosphorylations, Cdks are 
regulated by Cdk inhibitors (CKIs). The CKIs are divided into two protein   15 
families based on their structure and Cdk targets. The first family, consisting of 
p16
INK4A, p15
INKB, p18
INK4C and p19
INK4D, is called INK4 family since they target the 
catalytic subunit of Cdk4 and Cdk6 and therefore, is specific only
 for early G1 
phase. The second family, named the Cip/Kip family, consist of p21
Cip1, p27
Kip1 
and p57
Kip2 and inhibit most Cdks and is not specific for a particular phase. 
Cip/Kip proteins can both interact with cyclin and Cdk in the complex while INK4 
proteins only bind to Cdk.  
The INK4 family proteins prevent association with D-type Cyclins by inhibiting 
Cdk4 and Cdk6. The Cip/Kip family members, on the other hand, interfere with 
the activities of cyclin E-, and A-dependent
  kinases. The Cip/Kip proteins are 
potent
 inhibitors of cyclin E- and A-dependent Cdk2, but positive regulators
 of 
cyclin D-dependent kinases Cdk4 and Cdk6 (Sherr and Roberts, 1999).  
 
  p21, which is particularly relevant to this thesis, is a potent inhibitor of Cdk2 
activity and its levels normally increase in early G1 to prevent further cell cycle 
progression. Increased p21 levels can also occur because of transcriptional 
activation caused by the p53 transcription factor, as a response to DNA damage. In 
addition to Cdks, p21 can also interact with PCNA that is an elongation factor for 
DNA polymerase δ, as well as a component of the DNA repair machinery. This 
binding inhibits the ability of PCNA to function in DNA replication but not DNA 
repair (Li et al., 1994). As cyclin D-cdk4/6 increases, it titrate the level of p21 by 
sequestering it as part of a complex containing PCNA. Later, this titration allows 
CyclinE/Cdk2 to become activated, which is required for cell cycle progression 
through G1/S.  
 
  Numerous growth inhibitory signals such as IFNs and TGF-β, upregulate 
members of both CKI families. Upregulation of the INK4 proteins resulting in 
inactivation of Cdk4/6 leads to disruption of CyclinD/Cdk/Cip/Kip complexes.   
Cip/Kip inhibitors are released from the complex which in turn can bind to and 
inhibit CyclinE/Cdk2 complexes leading to cell cycle arrest in G1/G0. 
 
  The cell cycle regulatory factors are responsible for key events in the cell cycle 
progress. Any failure of the regulatory system can result in cancer (for review see 
(Kastan and Bartek, 2004, Massague, 2004)). 
 
Apoptosis 
Apoptosis, or programmed cell death, is a naturally occurring process in the body 
that is necessary during development, for the immune defence and for 
homeostatis.  
Apoptosis is induced by a variety of death signals, both extrinsic and intrinsic, 
including withdrawal of growth factors, damages caused by chemical compounds, 
irradiation or endogenous molecules such as oxidants. Morphologically, apoptosis 
is characterized by chromatin condensation, cell shrinkage (in early stage), nucleus 
and cytoplasm fragmentation and formation of membrane-bound apoptotic bodies 
which can be taken up and destroyed by phagocytes. These fragments are enclosed 
in membranes so they can not harm nearby cells and cause an inflammatory 
reaction.  In contrast to apoptosis, cells undergo another form of cell death called 
necrosis which is an uncontrolled cell death and is usually a consequence of a   16
pathophysiological  condition, such as infection, inflammation or ischaemia. In 
necrosis cells swell, rupture and the released intracellular contents can damage 
surrounding cells and often cause inflammation (for review see (Adams, 2003, 
Jiang and Wang, 2004)).  
 
  Several human diseases, such as cancer, neurodegenerative disorders, and 
autoimmune diseases, have been directly linked to genetic defects in the apoptotic 
pathways. Failure of the death machinery results from the mutation of genes 
coding for factors involved in the initiation, mediation, or execution of apoptosis 
(Green, 1998, Mullauer et al., 2001). It is therefore crucial that these mechanisms 
are tightly regulated. The mechanisms involved in the regulation of cell death 
involve many factors. There are two major initiating pathways, the death receptor 
(extrinsic) pathway and the mitochondrial (intrinsic) pathway. These two 
pathways activate caspases that are the main effectors of the apoptosis. The 
caspases are a group of cysteine proteases that exist within the cell as inactive pro-
forms (zymogens) which can be cleaved to form active enzymes following the 
induction of apoptosis. The extrinsic pathway is mediated by the activation of so 
called death receptors which are cell surface receptors that transmit apoptotic 
signals after ligation with their specific ligands. Death receptors belong to the 
tumor necrosis factor receptor (TNFR) gene superfamily, including TNFR-1, Fas 
(CD95), and the TRAIL receptors (Ashkenazi, 2002). When death receptors bind 
their ligand a signal is transmitted to the cytoplasm that leads to activation of 
caspase 8 which in turn activates downstream effector caspases leading to 
phagocytosis of the cell. The intrinsic pathway involves Bcl-2 family proteins 
which are both anti- (Bcl-2, Bcl-xl and Bcl-x) and pro-apoptotic (Bax, Bak, Bid 
and Bin). This family of proteins are regulated by factors including the PI-3K/Akt 
pathway inducing survival and the p53 tumour suppressor protein inducing 
apoptosis (due to DNA damage or overexpression of genes).  Regulation of 
apoptosis by Bcl-2 proteins mainly seems to be depending on release of 
cytochrome c from mitochondria. Cytochrome
 c is normally sequestered between 
the inner and outer membranes
 of the mitochondria and is released into the cytosol 
in response to a variety of proapoptotic
  stimuli (Jiang and Wang, 2004). The 
released cytochrome c and Apaf-1 bind to molecules of procaspase 9 and ATP and 
form a complex (an apoptosome) that activates other downstream caspases 
(caspase 3). The extrinsic pathway can also induce release of cytochrome c 
through a Bcl-2 family member, Bid. Cross-talk between the two pathways exists 
and enhancement of apoptosis through Bid protein is such an example. The Bcl-2 
family members with anti-apoptotic abilities stabilize the mitochondria by 
preventing cytochrome c release and in that way protect the cell from apoptosis.  
 
Signaling Pathways for Growth and Differentiation 
A cell needs to communicate with its environment to be able to generate 
appropriate cellular responses. The responsiveness of a cell relies on detection 
systems that sense changes outside the cell and are coupled to signal transduction 
pathways. There are several different signal transduction pathways existing which 
involve different signal molecules (such as growth factors, hormones, cytokines, 
ions and adhesion molecules on neighbouring cells) and different receptors (such   17 
as tyrosine kinases, G-protein coupled receptor, nuclear receptors). Here I will 
only focus on the signals and signal pathways that have direct relevance to this 
thesis. 
 
IFN-γ Signaling Pathway 
Interferons (IFNs) were originally described as agents capable of protecting cells 
from viral infections by interfering with viral replication. They belong to the large 
class of glycoproteins known as cytokines and are involved in antiviral defence, 
the regulation of cell growth and immune response. IFNs are subdivided into two 
classes on the basis of structural and functional criteria as well as the stimuli that 
induce their expression. The type I IFNs consist predominantly of IFN-α and –β 
and type II only of IFNγ. The type I IFNs are induced in most cells by viruses and 
dsRNA while IFNγ is mainly secreted by T helper type 1 (Th1) lymphocytes and 
natural killer (NK) cells. It has been shown that IFNγ is also secreted by B cells, 
natural killer T cells, and professional antigen-presenting cells (APCs). IFNγ 
production is controlled by cytokines secreted by APC, especially interleukin (IL)-
12 and IL-18. One way to regulate IFNγ action is to control its production. IFNγ 
activity can also be controlled through modulation of IFNγ signalling. These two 
classes of IFNs activate transduction pathways via different cell surface receptors 
(Stark et al., 1998). Binding of both type I and II IFNs result in the activation of 
Janus kinases (JAK) that phosphorylate cytoplasmic transcription factors called 
signal transducer and activator of transcription (STATs). Phosphorylated STATs 
translocate to the nucleus, bind specific DNA sites and direct transcription of IFN 
responsive genes. There are four mammalian JAKs (JAK1, JAK2, JAK3 and 
Tyk2) and seven STATs (STAT1, 2, 3, 4, 5a, 5b and 6) identified (for review see 
(Aaronson and Horvath, 2002)).  
 
 IFNγ exerts its functions by binding to a specific receptor composed of two 
subunits, IFNGR1 and IFNGR2 which in unstimulated cells are preassociated with 
JAK1 and JAK2, respectively. IFNγ bind to two IFNGR1 subunits and causes a 
conformational change generating binding sites for IFNGR2 subunits. The 
recruitment of the IFNGR2 into the complex brings JAK1 and JAK2 closer to 
each other. The inactive JAK2 kinase undergoes autophosphorylation and 
activation, which in turn allows JAK1 to be transphosphorylated by JAK2. The 
activated JAK1 then phosphorylates functionally essential tyrosines on residue 
440 near the C-terminus of each IFNGR1, creating paired docking sites for 
STAT1. Afterwards two latent phoshorylated STAT1 molecules bind these sites 
through their Src homology (SH-2) domain and get phosphorylated by the receptor 
kinases at tyrosine 701 in their C- terminal. The activated STAT1 proteins 
dissociate from the receptor complex, form a homodimer which subsequently 
translocates into the nucleus and bind the gamma activated site (GAS) to activate 
transcription (for review see(Schroder et al., 2004)). To a lesser extend, the 
STAT1 homodimers are also able to bind to IFN-stimulated response element 
(ISRE) promoter regions in target genes to regulate transcription. Pathways other 
than JAK/STAT are also involved in IFN signaling, but their mechanisms are less 
clear. The best studied ones are the MAPK cascade, the components of the T cell 
receptor signaling cascade and the PI3 kinase pathway (Kalvakolanu, 2003). 
   18
  Transcriptional regulation by the JAK/STAT pathway is involved in most of the 
biological functions of interferons such as antiviral response, cell growth 
inhibition, differentiation, tumour suppression and regulation of apoptosis. STAT1 
has shown to be required for the antiproliferative effects of IFNs. For instance, 
expression of the Cdk inhibitor p21 is upregulated by IFNγ whereas c-myc, cyclin 
D3 and cdc25a expression is decreased in response to IFNα (Chin et al., 1996, 
Kominsky et al., 1998, Ramana et al., 2000, Tiefenbrun et al., 1996).  It has been 
shown that STAT1 and 2 interact with transcriptional coactivators such as Nmi 
(N-Myc-interacting protein) and CBP/p300 (Bhattacharya et al., 1996, Zhu et al., 
1999). These interactions are important since antibodies directed against 
CBP/p300 blocks transcription induced by IFNγ.  
 
Retionic Acid (RA) 
Vitamin A (retinol) and its derivates (retinoids) are essential for life and have 
important roles in embryonic development and cellular differentiation. In the diet, 
Vitamin A is obtained as retinyl ester from meat or from β-carotene found in a 
variety of plants. Vitamin A is absorbed by intestinal enterocytes, esterified to 
retinyl esters and stored in the lever. The retinyl esters are cleaved to form retinol 
which is released into the circulation bound to retinol binding protein (RBP) 
Retinol enters the target cell and is oxidised to retinal and retinoic acid (RA). 
Biologically active metabolities of RA include all-trans RA (atRA), 9-cis RA, 13-
cis RA and 3,4-didehydro RA. Once RA has been synthesised in the cell, it enters 
the nucleus and binds specific nuclear receptors that regulate gene transcription. 
There are two classes of nuclear receptors, retinoic acid receptors (RARs) and 
retinoid X receptors (RXRs). Three subtypes of both RARs (RARα, -β, -γ) and 
RXRs (RXRα, -β, -γ) have been cloned, all belonging to steroid/thyroid hormone 
family of transcription factors. These ligand-induced transcription factors possess 
specific DNA binding sites and RA binding sites, namely retinoic acid response 
elements (RAREs) (Chambon, 1996, Marill et al., 2003). Different forms of active 
RA have been found to bind different receptors. For instance, atRA binds mainly 
the RAR receptor while 9-cis RA interacts with both RAR and RXR receptors. 
These receptors form hetero- or homodimers to exert their function. RAR 
homodimers or RAR/RXR heterodimers can signal through RAREs upon ligand 
binding whereas RXR/RXR binds RXREs in response to 9-cis RA stimulation. In 
the absence of ligand, RAR and RXR receptors bind DNA and repress genes by 
interacting with HDACs via coreppressors (CoR) and Sin3 (Glass and Rosenfeld, 
2000) (See the section about transcriptional repression). Upon ligand binding, a 
conformational change in ligand-binding domain occurs which disrupts CoR 
binding and allows interaction with coactivators (CoAs) instead. CoAs recruit 
histone acetyltransferases (HATs) complexes which leads to chromatin 
decondensation and activation of target genes. This will be discussed further in the 
section concerning transcription. 
 
It is well known that RA is important for development and for regulation of 
differentiation and proliferation of numerous cell types throughout adult life. 
Already in 1925 a link between vitamin A deficiency and tumour development in 
epithelial cells was reported (Wolbach and Howe, 1978). It is well documented 
that RA can promote differentiation in various cells in vitro including   19 
neuroblastoma, myelogenous leukemia and hematopoetic cells (Breitman et al., 
1980, Sidell, 1982). This important function has made RA a potential drug for 
cancer treatment (Altucci and Gronemeyer, 2001, Soprano and Soprano, 2002). 
RA is already used successfully to treat various types of cancers, including acute 
promyelocytic leukemia, breast cancer, and precancerous lesions such as oral 
leukoplakia and cervical dysplasia (Dragnev et al., 2000). In addition, retinoids 
have been shown to delay the development of skin cancer. 13-cis RA is used to 
treat neuroblastoma patients and good effects of this treatment is reported (for 
review see (Matthay et al., 1999, Reynolds et al., 2003)). 
 
Vitamin D3 
Vitamin D3 is involved in calcium homeostatis, bone formation and modulation of 
cell growth and differentiation. Vitamin D3 is a secosteroid that is produced in the 
skin upon exposure to ultraviolet light or obtained from the diet. The biologically 
active form of vitamin D3 is 1,25-dihydroxyvitamin D3 (VitD3). Two successive 
hydroxylations are required to form the active metabolite of vitamin D3. The 
biological effects of VitD3 are mediated through vitamin D receptor (VDR) which 
is a nuclear receptor. Upon binding its ligand (VitD3), VDR heterodimerize with 
RXR and bind vitamin D responsive elements (VDREs) in the promoters of target 
genes, genes that are usually involved in regulation of VitD3 metabolism and bone 
formation (for review see (Lin and White, 2004)). Growth arrest and 
differentiation of various cell types in vitro such as U937 myelomonocytic cells 
and keratinocytes is induced by VitD3(Olsson et al., 1983, Smith et al., 1986) and  
p21 is upregulated in these differentiated cells (Liu et al., 1996). In hematopoetic 
cells, VitD3 treatment leads to downregulation of the c-myc protooncogene 
(Reitsma et al., 1983). 
 
TPA  
Phorbol esters and their derivatives are potent tumour promoting agents but it has 
also been shown that they are able to induce growth arrest/inhibition and 
differentiation of various cell types such as neuronal and myeloid cells (Harris and 
Ralph, 1985, Pahlman et al., 1981). They can also promote proliferation of certain 
cell types. The three most widely used active phorbols are 4ß-12-O-
tetradecanoylphorbol-13-acetate (TPA),
  phorbol
  12-myristate-13-acetate (PMA) 
and 4ß-phorbol-12,13-dibutyrate (PDBu). The best known receptors for these 
substances are the novel and classical isotypes of protein kinase C (PKC), which 
are members of the large family of Serine/Threonine protein-kinases (for review 
see (Parker and Murray-Rust, 2004)).  PKC is activated by the physiological 
second messenger diacylglycerol (DAG). Phorbol esters can mimic the effect of 
DAG and activate PKC which in turn can activate other kinases such as ERK.  
 
  Activation of classical and novel types of PKC by TPA shortcuts the normal 
activation pathway of PKC. It has been reported that inhibitors of PKC restrain 
differentiation of neuroblastoma cells (Fagerstrom et al., 1996). The 
antiproliferative effect of TPA has been characterized by c-myc downregulation 
and p21 upregulation for instance in hematopoetic, neuroblastoma and breast   20
cancer cell lines ((Hammerling et al., 1987, Mitchell and El-Deiry, 1999, Todd 
and Reynolds, 1998)).  
 
 
Transcriptional Regulation 
 
Transcription of the different classes of RNAs in eukaryotes is carried out by three 
different polymerases. RNA pol I synthesize the large rRNAs, RNA pol II 
synthesizes the mRNAs and some small nuclear RNAs (snRNAs, which is 
involved in splicing) and RNA pol III synthesizes a variety of small stable RNAs, 
including the 5S rRNA and the tRNAs.  
Regulation of gene expression is a central step in the maintenance of cellular 
homeostasis. Gene expression can be regulated at multiple steps. These steps can 
include: initiation of transcription, chromatin structure, processing of the 
transcript, transport to the cytoplasm, translation of mRNA, stability of mRNA 
and protein activity. Even though there are multiple stages where control of gene 
expression can occur, it is well established that the majority of regulatory events 
take place at the initiation of gene transcription. Various components are involved 
in every step of the regulation. In this chapter the steps and components involved 
in RNA PolII mediated transcriptional regulation will be briefly discussed.  
 
Initiation of transcription 
RNA polymerase II (RNA pol II) is responsible for the transcription of protein-
coding genes in eukaryotes, but the polymerase can not initiate transcription on its 
own. Additional proteins, so called general transcription factors (GTFs) that 
directly or indirectly interacts with the RNA pol II, are required. These proteins 
have to assemble with RNA polymerase II into a complex on the promoter DNA. 
The promoter region in a gene contains different sequence elements, including 
TATA-box, the initiator (Inr) and the downstream promoter element (DPE), which 
allow regulatory components to bind and exert their activity. The start of 
transcription by RNA pol II is directed by these core promoter elements.  
 
  GTFs include five basal factors, TFIIB, TFIID, TFIIE, TFIIF and TFIIH. TFIIA 
is the sixth factor and it potentiates the magnitude of transcription (Reese, 2003). 
TFIID binding is thought to be the first step in transcription initiation. TFIID is a 
multi-component transcription factor consisting of a DNA binding subunit, 
TATA-binding protein (TBP), and several, at least 14, TBP-associated factors 
(TAFs). The binding of TBP causes a bend in the DNA which creates a platform 
for the interaction of the remaining factors. The next GTF to bind the promoter is 
TFIIB, which interacts with TBP and recruits RNA pol II partly through an 
interaction with the small subunit of TFIIF. TFIIB stabilizes TFIID at the 
promoter by contacting TFIID and sequences next to the TATA box. TFIIB, in 
turn, recruits TFIIH which contains helicase and kinase activities. TFIIH catalyzes 
ATP-dependent melting of the promoter (separation of the two DNA strands) at 
the transcriptional start site. The kinase of TFIIH (cyclinH/Cdk7) phosphorylates 
the C-terminal domain of the RNA pol II largest subunit (Rbp1). TFIIH appears to 
be dependent on TFIIE for incorporation into the pre-initiation complex (PIC).   21 
Both TFIIF and TFIIH are necessary for promoter clearance and the progression 
into the elongation phase (Reese, 2003, Sims et al., 2004b). Elongation factors 
involved in the elongation process are divided into two classes; negatively acting 
factors that inhibit transcription and positively acting factors that overcome the 
inhibition (Sims et al., 2004a). The positive transcription elongation factor b (P-
TEFb) complex, which consists of a common catalytic subunit (Cdk9) and one of 
several regulatory cyclins T1, T2 and K, phoshorylates CTD of RNA pol II and 
allows the elongation to proceed. NELF and DSIF are examples of negatively 
acting factors. It has been suggested that NELF and DSIF function through 
interactions polymerase containing a hypophosphorylated CTD. Additionally, 
pausing of RNA pol II is suppressed by a various collection of proteins, including 
TFII, ELL and Elongin. It should be also mentioned that beside elongation 
process, several steps in mRNA maturation, including pre-mRNA
  capping, 
splicing, 3'-end processing and export,
  are modulated via interactions with the 
RNAP II transcript
 elongation complex (Sims et al., 2004a). 
 
  Transcription of most genes is regulated by specific regulatory transcription 
factors that affect the transcription rate positively (activotors) or negatively 
(repressors). These proteins interact with specific regulatory DNA sequences 
including enhancers/silencers, upstream promoter elements and initiators in 
eukaryotes. In order to activate or repress transcription these factors need to 
interact with the PIC. This interaction involves contacts with components of 
mediator complex and with TAFs. The DNA-binding transcription factors have at 
least two important domains: a DNA binding domain (DBD) that positions the 
protein on specific sequences and a transactivation domain (TAD) that activate 
transcription by for instance recruiting or accelerating the assembly of GTFs on 
the promoter. The negative regulating transcription factors contain a domain that is 
able to repress the recruitment of RNA pol II or is able to interact with 
corepressors. The DNA binding transcription factors are divided into different 
groups depending on the structural motifs they possess. The four well described 
motifs are the basic-helix-loop-helix (HLH) motif, the basic leucine zipper (LZ), 
the zinc finger (ZF) and the helix-turn-helix (HTH) domain. 
 
Coactivators and coreppressors 
Transcriptional regulation is not only dependent on TF activation or repression. 
Additional proteins called coregulators (coactivator/corepressor) are also reqired 
in transcriptional regulation. Studying the role of these coregulators is necessary to 
understand transcriptional regulation in eukaryotes. 
 
  Coactivators usually do not bind DNA and are recruited to target promoters 
through protein-protein interactions with transcription factors. They often contain 
enzymatic activities necessary for an alteration in chromatin structure. 
Coactivators can broadly be divided into three classes (Spiegelman and Heinrich, 
2004). The first class consist of proteins that modify histones leading to a greater 
access of other proteins to DNA. For instance, p300, CBP and histone 
acetyltransferases (HATs) are examples of this class. Members of the 
TRAP/DRIP/Mediator/ARC complex constitute the second class of coactivators. 
These proteins bind transcription factors, recruits RNA pol II and interact with the   22
general transcription machinery. The last group is protein complexes of the yeast 
SWI/SNF family (mammalian homologs BRG1 or BRM) which have ATP-
dependent chromatin remodelling activities. 
 
  Corepressors have the opposite effect on chromatin structure compared to the 
coactivators. These proteins in general coordinate the inactivation of 
transcriptionally active complexes. Their direct interaction with DNA binding 
transcription factors and recruitment of chromatin modifying enzymes leads to an 
inactive state of the nucleosome making the chromatin inaccessible to other 
proteins. Examples of such proteins are nuclear hormone receptor corepressor 
(NCoR) and thyroid hormone receptors (SMRT). Corepressors are often 
associated with histone deacetylase (HDAC) activity (see below).  
 
Histone Modifications and Chromatin Remodeling 
  In eukaryotes, genomic DNA is packaged into chromatin which is composed of 
DNA and proteins. Two superhelical turns of DNA are wrapped around a histone 
octamer which forms the nucleosome core particle. The nucleosomes form the 
basic repeating unit in chromatin and consist of four histone partner, one H3-H4 
tetramer and two H2-H2B dimers (for review see (Spiegelman and Heinrich, 
2004)). The packaging of DNA into nucleosomes makes it less accessible to both 
sequence specific and general transcription factors. For transcription to take place 
this highly ordered and condensed chromatin structure must be altered. There are 
two elegant mechanisms that have evolved to modify chromatin structure: 
modification of chromatin by acetylation/deacetylation  of histones and 
nucleosome remodelling.  
 
  Histones are targets for a variety of post-translational modifications (often occur 
on tail domains of these proteins) including acetylation, methylation, 
phosphorylation and ubiquitylation (Strahl and Allis, 2000). Acetylated histones 
have been associated with actively transcribed genes whereas deacetylated 
histones have preferentially been found in silenced genes. The HATs and HDACs 
regulate acetylation and deacetylation of the conserved lysine residues present in 
histones. Acetylation of histones by HATs leads to a less condensed chromatin 
structure and increase the accessibility to GTFs, the RNA pol II and to additional 
regulatory proteins. A quantity of transcriptional coactivators have been shown to 
have HAT activity, including CREB binding protein (CBP) and the related protein 
p300, p300/CPB-associated factor (P/CAF), and the p160 family (SRC-1, TIF2 
and Pcip). There are proteins with intrinsic HAT activity, for instance TAFII250 
which is a TFIID subunit that has critical function in transcription initiation 
(Mizzen et al., 1996). Another example is Nut1 that is part of the yeast mediator 
complex, which is directly associated with RNA polymerase II (Lorch et al., 
2000). Many of the HATs are components of multisubunit complexes. Two well-
known example is the yeast SAGA and ADA complexes (Grant et al., 1997). 
hGCN5 and P/CAF are the mammalian homologs of GCN5. Both yeast and 
mammalian GCN5 type coactivators contain a Tra1/TRAPP polypeptide which 
has been shown to interact with specific coactivators, such as c-Myc (McMahon et 
al., 1998, Saleh et al., 1998).  
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  HDACs carry out their effects by removing acetyl groups from lysines in the N-
terminal tails of histones and are correlated with transcriptionally repressed state. 
Various proteins have been shown to possess intrinsic HDAC activity (Grozinger 
and Schreiber, 2002). Mammalian HDACs are ordered into three classes (class I, 
II and III) based upon sequence similarity to the yeast HDACs (Rpd3, Had1 and 
Sir2). Class I consist of HDACs 1, 2, 3 and 8, class II of HDACs 4, 5, 6, 7, 9 and 
10. HDAC1 and HDAC2, members of class I HDACs, are the best characterized 
HDAC proteins and are usually found in stable, multicomponent complexes of 
proteins, which are then recruited by DNA binding proteins (such as 
coreppressors). Sin3, NCoR/SMRT, Mi2/NuRD and CoREST complexes are 
among these complexes. The Myc antagonist, Mad proteins has been shown to 
interact with Sin3/NCoR complexes to exert their function and to repress 
expression of myc target genes (Ayer et al., 1995, Hassig et al., 1997, Laherty et 
al., 1997, Schreiber-Agus et al., 1995, Sommer et al., 1997).  
There is accumulating evidence that transcription might also be regulated by 
acetylation of non-histone proteins, such as p53, tubulin and various transcription 
factors (Gu and Roeder, 1997).  
 
  Another way of modifying chromatin structure is by ATP-dependent chromatin 
remodelling complexes as SWI/SNF, ISWI, RSC and Mi-2/NuRD, which alter 
chromatin structure by changing the location or confirmation of the nucleosome 
without covalent modifications. These complexes all have ATPase activity and 
they increase accessibility to DNA as well as to histones. The yeast SWI-SWF 
complex is the founding member of this family of ATP-dependent chromatin-
remodelling complexes. Its hallmark subunit which possesses intrinsic ATPase 
activity is SWI2/SNF2. Brahma (Brm) is the Drosophila homolog of SWI2/SNF2 
whereas hBRM/hSNF2a and BRG1/hSNF2b are the human homologues. Some 
activators have been shown physically or functionally to interact with SWI/SNF 
activity. For instance C/EBPβ activator and c-Myc proto-oncoprotein interacts 
directly with subunits of mammalian SWI/SNF complexes (for review see (Naar et 
al., 2001)). SWI/SNF complexes can also function as repressor of transcription. 
This has been demonstrated by physical presence of SWI/SNF components at 
repressed promoters (for review see (Martens and Winston, 2003)).   
 
Myc/Max/Mad Network 
The myc proto-oncogene family is shown to be involved in a number of essential 
cellular processes and deregulation of this gene is frequently observed in a variety 
of human cancers. This has led to an extensive study of Myc to understand its 
function and its involvement in carcinogenesis (for review see (Oster et al., 
2002)).  
 
 The myc oncogene was originally identified in avian myelocytomatosis 
retrovirus for over two decades ago (v-myc) (Sheiness and Bishop, 1979, Sheiness 
et al., 1978). Shortly after, a cellular homolog of v-myc was isolated in chicken 
(Vennstrom et al., 1982) which was capable to induce myeloid leukaemia, 
sarcomas, liver, kidney and other types of tumours in chicken (Gonda et al., 1982). 
It was also discovered that the human c-myc homolog is constitutively active in 
Burkitt’s lymphoma due to translocation involving c-myc and Ig-locus (Dalla-Favera et al., 1982, Taub et al., 1982). c-myc is evolutionary conserved and has 
been identified in all vertebrates, including zebrafish (Schreiber-Agus et al., 1993) 
and in some non-vertebrates such as the sea star Asteria vulgaris (Walker et al., 
1992) and Drosophila (Gallant et al., 1996). myc has not yet been identified in 
yeast or Caenorhabditis elegans. Other myc family members, the N- and L-myc, 
were subsequently discovered as amplified or highly expressed genes in 
neuroblastoma (Kohl et al., 1983, Schwab et al., 1983) and in small lung cancer 
(Nau et al., 1985), respectively. B- and S-myc, are two additional members of the 
myc family, that have only been identified in rodents and are not well-
characterized (Ingvarsson et al., 1988, Sugiyama et al., 1989). c-, N-, and L-myc 
share similar genomic organisation and as well as evolutionary conserved domains 
that are functionally important protein regions. They all consist of three exons: an 
untranslated exon (exon 1) and two exons containing protein coding sequence 
(exon 2 and 3). Expression of these members of the myc family is deregulated in 
many different tumours. L-myc seems to have a weaker oncogenic potential 
compared to c- and N-myc (Barrett et al., 1992). c-, N-, and L-myc seem to have 
similar functions and to various degrees they seem to be able to substitute for each 
other’s activities in different biological processes. For instance, it has been shown 
that insertion of N-myc into c-myc locus rescued the c-myc null phenotype 
(Malynn et al., 2000) indicating similar function of c- and N-myc. c-myc and N-
myc encodes essential genes and embryos carrying c-myc deletion die before birth 
at day 10.5 (Davis et al., 1993). It should also be mentioned that the expression 
pattern of these three genes differ during development and in the adult pointing 
towards different roles (Charron et al., 1992, Davis et al., 1993, Jakobovits et al., 
1985, Stanton et al., 1992, Zimmerman et al., 1986).  
 
Myc/Max/Mad Network and the structure of its members 
The Myc family members belong to basic/helix-loop-helix/leuzine zipper 
(bHLHZip) family of transcription factors and they encode short-lived 
phoshoproteins (64 and 67 kDa). The structure of Myc is shown in figure 3. The 
bHLHZip domain located at the C-terminus of the protein is responsible for DNA-
binding and protein-protein interaction (Luscher and Larsson, 1999). 
c-Myc
Max
Mad1
SID
Zip HLH b NLS acidic MB2 MB1
TAD
 
Figure 3: Structure of c-Myc, Max and Mad. Domains of functional importance are 
indicated. TAD: transcriptional activation domain, MB: Myc box, NLS: nuclear localisation  
sequence, b: basic region, HLH; helix-loop-helix, Zip: leucine zipper, SID: Sin3 interaction 
domain 
 
The N-terminus of the Myc protein harbours a transactivation domain (TAD) 
involved in Myc-regulated transcription. The TAD contains two evolutionary 
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conserved regions, namely Myc box I and II (MBI, II). MBI contains several 
phosphorylation sites that are important for the regulation of Myc protein stability 
by the ubiquitin/proteasome pathway (Flinn1999, Sears2000, Salghetti 2000, 
Bahram 2000,Gregory&Hann2000.Welcker 2004 (PNAS) Nakayama 2004 
(EMBO)). It has been shown that phosphorylation of Thr58 serves as a 
recognition signal for the E3 ligase Fbw7 (Welcker et al., 2004, Yada et al., 2004). 
Further, MBI is also required for cell transformation. MBII mediates interaction 
with many partners (see below) and is necessary for all biological activities of 
Myc, including transcriptional activation and repression, proliferation, block of 
differentiation, apoptosis and transformation (Grandori et al., 2000). Additionally, 
MBII serves as an interaction surface for the E3 ligase Skp2, leading to 
ubiquitylation and subsequent degradation by the proteasome (Kim et al., 2003, 
von der Lehr et al., 2003). Additional sites/domains in Myc protein are: a nuclear 
localisation site (NLS) important for import into the nucleus and a central acidic 
domain that contain several phosphorylation sites that might be important for 
function.  
 
  Myc needs to dimerize with another bHLHZip protein, Max; to be able to 
activate transcription. This discovery was one of the major breakthroughs in Myc 
research (Blackwood et al., 1992, Prendergast and Ziff, 1992). The Myc:Max 
dimers bind specific DNA sequences called E-boxes (CACGTG) and this 
interaction is of importance both for transcriptional activation and for the 
biological functions of Myc (Amati et al., 1993).  
 
  In addition to Myc, Max can also dimerize with other bHLHZip proteins 
including Mad family proteins (Mad1, Mxi1, Mad3 and Mad4), Mnt and Mga 
(Ayer et al., 1993, Hurlin et al., 1995a, Hurlin et al., 1997, Hurlin et al., 1999, 
Zervos et al., 1994). These proteins contain conserved regions: the bHLHZip 
domain in the C-terminus and a Sin3-interaction domain (SID) in the N-terminus 
which mediates transcriptional repression. Mad/Mnt proteins have been shown to 
act as antagonists to Myc in certain functions. They bind to similar if not identical 
E-boxes and they compete with Myc to bind Max and exert their function. 
Mad/Mnt family proteins together with Myc and Max form the Myc/Max/Mad 
network there Max plays a central role (see figure 4). Different cellular responses 
can be achieved depending on whether Max form complex with Myc or Mad. c-Myc
Max
N-Myc
L-Myc
Mads
Mnt
Mga
Nmi1
BRCA1
TFII-I
AP2
p107
YY1
TBP
Miz-1
TRRAP
Bin1
mSin3A
mSin3B
proliferation
apoptosis
growth arrest
differentiation
survival
HAT
HDAC
Figure 4: The Myc-Max-Mad network and some associated proteins 
  
  Further a Max-like protein, Mlx; was identified and characterized as a Mad1 
binding protein (Billin et al., 1999, Meroni et al., 2000). Mlx can form dimers with 
Mad1, Mad4 and Mnt. The function of Mlx in Myc/Max/Mad network is not well 
understood yet. It is known that Mad/Mlx heterodimers bind specifically to E-
boxes and have the ability to repress transcription in an msin3 dependent manner. 
An additional partner to Mlx is MondoA and Mlx/MondoA complexes are 
believed to activate transcription by binding E-boxes in target gene promoters. 
Mlx consequently, can both activate and repress transcription depending on the 
protein it is interacting with. Another Max interacting protein is Mga which only 
share the bHLHZip domain in common with other Myc/Max/Mad network 
proteins (Hurlin et al., 1999). Mga binds E-boxes but in contrast to Mad/Mnt 
proteins it does not contain SID and therefore believed that it exert its function not 
dependent on mSin3.  
  c-Myc can interact with many other proteins both in the N- and C-terminus. For 
instance TBP, TRRAP, Bin1 and p107 interact with N-terminus (Beijersbergen et 
al., 1994, Gu et al., 1994, Hateboer et al., 1993, McMahon et al., 1998, Sakamuro 
et al., 1996) while TFII-I, YY1, Miz-1, Nmi, BRCA1 and AP-2 bind the C-
terminus of c-Myc (Bao and Zervos, 1996, Gaubatz et al., 1995, Peukert et al., 
1997, Roy et al., 1993, Shrivastava et al., 1993, Wang et al., 1998b). 
 
Transcriptional Regulation 
Myc/Max/Mad network proteins can regulate transcription both by involving 
histone-modifying enzymes and interacting with the basal transcription machinery. 
Antagonistic biological functions of Myc and Mad can depend on the recruitment 
of counteracting enzymes, HATs and HDACs. 
 
Myc activates transcription by interacting with the coactivator TRRAP 
(Transformation-transactivation domain- Associated Protein) through its TAD 
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domain or more specifically via MBII (McMahon et al., 1998, Patel et al., 2004a). 
TRRAP is a component of various complexes with HAT activity, for 
instanceGCN5/PCAF or Tip60 (Fernandez et al., 2003, Frank et al., 2003, 
McMahon et al., 2000). Interaction of Myc with HAT containing complexes seem 
to be essential for Myc induced transformation, since dominant negative mutants 
of TRRAP has been shown to inhibit transformation by Myc (McMahon et al., 
2000). It has also recently been shown that Myc interacts with CBP (cAMP 
response element binding protein) which is another coactivator with HAT activity 
(Vervoorts et al., 2003). Further, Myc has been observed to interact with other 
chromatin-remodeling enzymes, the Tip48 and Tip 49 which contain ATPase 
helicase activity. These proteins interact with Myc via MBII and have been shown 
to be essential for Myc-induced oncogenic transformation (Wood et al., 2000). 
Tip48 and Tip 49 can further bind Baf53 which is a component of STAGA 
(containing GCN5) and Tip60 complexes. GCN5, Tip48, Tip49, and Baf53 
proteins are part of various complexes which are involved in chromatin regulation 
either by ATP-dependent remodelling or histone acetylation (Frank et al., 2003, 
McMahon et al., 1998, Nikiforov et al., 2002b, Park et al., 2001, Patel et al., 
2004a). It has further been shown that interaction of Myc with the E3 ligase Skp2 
does not only lead to ubiquitylation and proteasomal degradation (as mentioned 
above) but is also needed for the transcriptional activity of Myc (Kim et al., 2003, 
von der Lehr et al., 2003). Additionally, Myc has also been reported to interact 
with other protein complexes involved in transcriptional regulation. For instance, 
Myc binds INI1 which is a homologue of yeast SNF5 protein and a subunit of 
SWI/SNF complex involved in chromatin remodelling in an ATP dependent 
manner. Dominant negative mutants of INI1 inhibit c-Myc induced transcription 
(Cheng et al., 1999). Additionally, Myc can directly interact with TBP which is a 
component of the basal transcription machinery. Importance of this interaction for 
Myc function has unfortunately not been explored yet. But more recently it has 
been shown that Myc interact with cyclin T1 and Cdk9, components of a polII 
CTD kinase. This interaction has been shown to be sufficient for activation of a 
synthetic promoter construct suggesting that Myc stimulates elongation of 
transcription (Eberhardy and Farnham, 2002).  
 
In addition to its role as transcriptional activator Myc has also the ability to repress 
transcription. Transcriptional repression is, at least partially, mediated by 
interaction with Miz1 (Myc-interacting zinc finger protein 1) which binds the 
HLH-domain of Myc. c-Myc has been shown to suppress expression of several 
cell cycle/growth arrest genes, including gas1, p15
Ink4b, p21
Cip1, p27
Kip1 and gadds 
(Gartel and Shchors, 2003). Miz-1 binds to initiator (Inr) like elements of these 
genes promoters and upregulate their expression. By forming complexes with 
Miz1, c-Myc antagonizes this process and inhibits Miz-1 mediated transcriptional 
activation of these genes (Herold et al., 2002, Peukert et al., 1997, Seoane et al., 
2001, Staller et al., 2001, Wanzel et al., 2003) (Paper IV). Transcriptional 
repression of c-Myc through Miz1 will be further discussed in the Results and 
Discussion section.  
 
Mad proteins repress transcription by recruiting HDACs to the target gene 
promoters. The recruitment of HDACs is mediated through SID domain of Mad 
which directly bind to mSin3. mSin3, in turn, is part of a multisubunit complex   28
including, HDAC1 and 2, the corepressors N-CoR/SMRT and many other (Alland 
et al., 1997, Hassig et al., 1997, Heinzel et al., 1997, Laherty et al., 1997, Sommer 
et al., 1997). Removal of the acetyl groups by HDACs leads to a more compact 
state of chromatin resulting in
 transcriptional repression. In addition to HDACs 
mSin3 proteins has been shown to interact with other chromatin modifiers, such as 
hBrm ATPase of the SWI/SNF complex or Suv39H1 methyltransferase (Czermin 
et al., 2001, Kuzmichev et al., 2002, Sif et al., 2001, Vaute et al., 2002). However, 
so far, HDAC is the only chromatin modifying enzyme that is recruited by Mad. 
 
Target Genes of Myc and Mad 
Myc and Mad exert their functions by regulating expression of specific genes. At 
present there are several hundred of Myc target genes that have been identified 
(Boon et al., 2001, Coller et al., 2000, Orian et al., 2003). Recent studies indicate 
that Myc binds and regulates up to 10-15 % of all genes (Fernandez et al., 2003, 
Patel et al., 2004b). However, since different approaches have been used to 
identify these genes it is not well known how many of them are regulated directly 
by Myc. Many of potential target genes were identified by micraoarray-based 
screens. Several other approaches ranged from differential expression screens, 
promoter analysis and educated guesses to more recent methods such as 
microarray screens, SAGE and ChIP have been used to identify putative target 
genes. Some examples of Myc target genes are: cyclin D2, p21, p15, cdc25a, cdk4, 
cul1, involved in cell cycle progression; gadd45, p53 involved in apoptosis; 
ornithine decarboxylase (ODC), cad, α-prothymosin, eIF4E, eIF-2α involved in 
growth and metabolism, hTERT involved in immortalization and tip48, pcaf 
involved in transcription, VEGF, tsp-1, activin A involved in angiogenesis (for 
review see (Dang, 1999, Levens, 2002).  
 
  So far the identified Mad family target genes are not as many as Myc target 
genes because it has been studied less. Since Myc and Mad have antagonistic 
effects it was reasonable to assume that they regulate same set of genes. To 
address this question the basic region of Myc was replaced with the basic region 
of Mxi. Subsequent microarray analysis revealed that Myc and Mxi1 has both 
common and distinct target genes (O'Hagan et al., 2000). A screen for Mad1 target 
genes also showed that Myc and Mad1 have both common and distinct target 
genes (Iritani et al., 2002). Some of the common genes are ODC, hTERT, gas1 and 
cul1. Many of the nonoverlapping genes do not posses E-box sequences and 
possibly involve alternative partners for Myc and Mad/Mnt. For instance, Myc-
dependent repression of transcription involves the zinc finger protein Miz-1 which 
binds initiator-like sequences. Mad proteins probably can not recognize these sites 
and thereby is not able to control this particular set of genes (James and Eisenman, 
2002, Nikiforov et al., 2002a, Nikiforov et al., 2003, Orian et al., 2003). 
 
Biological function of Myc and Mad 
Myc is a multifunctional protein which regulates various distinct biological 
activities, including proliferation, differentiation, cell cycle progression, apoptosis 
and tumorigenesis. Myc is believed to regulate these functions by regulating the   29 
transcription of specific target genes discussed above. Mad family proteins 
function as Myc antagonists in many of these biological functions. 
 
  Several lines of evidence suggest that Myc functions as a positive regulator of 
proliferation in response to various mitogenic signals. For instance, it has been 
shown that Myc is expressed in proliferating cells and Myc expression is induced 
when cells are treated with different growth factors, cytokines and mitogens 
(Armelin et al., 1984, Campisi et al., 1984, Kelly et al., 1983, Rabbitts et al., 
1985). For the proliferation to take place it is necessary for cells to overcome the 
G1/S checkpoint. c-Myc has been reported to be sufficient to overcome this 
checkpoint and induce S phase in absence of mitogens (Eilers, 1999) The essential 
role of Myc in cell cycle has been supported by a large body of evidence. For 
instance, antisence Myc inhibits S phase transition (Heikkila et al., 1987). 
Eliminating Myc expression by other techniques such as SiRNA also interferes 
with G1/S transition for review see (Oster et al., 2002)). Further, it has been 
shown that null myc Rat1 fibroblasts grow slower and have a prolonged G2 phase 
G2?? (Mateyak et al., 1997). MEF c-myc knock-out cells support mentioned data 
above (de Alboran et al., 2001). Several genes involved in cell cycle regulation are 
among Myc target genes, including cyclin D1, D2, and cdk4. Myc has been shown 
to activate Cyclin E/Cdk2, by directly activating cyclin D1and D2, which 
sequester p27Kip1. This leads to activation of Cyclin E/Cdk2 complexes which 
are needed to overcome the G1/S checkpoint (Coller et al., 2000, Hermeking et al., 
2000, Luscher, 2001, Oster et al., 2002). Expression of other CKIs, such as 
p15INKB and p21Cip1 are also repressed directly by Myc, again leading to 
activation of CyclinD/Cdk4 and CyclinE/cdk2, respectively. p21Cip1 will be 
discussed further in results and discussion section. Inactivation of pRb is another 
important aspect of cell proliferation. c-Myc upregulates Id2 which in turn binds 
and inactivates pRb (Lasorella et al., 2000). 
 
Mad proteins are involved in pathways that negatively affect cell proliferation and 
are generally expressed in differentiated cells (see below). There is also evidence 
that some mad family genes, mxi1,  mad3 and mnt, are expressed during 
proliferation and in non-differentiated cells (Hurlin et al., 1996, Pulverer et al., 
2000, Queva et al., 1998, Zervos et al., 1993). One possible explanation to this is 
that these Mad/Mnt proteins have a function to antagonize or modulate the effects 
of Myc during certain periods of cell proliferation and differentiation. Ectopically 
overexpressed Mad/Mnt family proteins have been studied in tissue cultures and 
transgenic mice. Mad1, Mxi1, Mad3 andMad4 interfered with the proliferation of 
the cells and blocked cooperative transformation by Myc and Ras (Cerni et al., 
1995, Chen et al., 1995, Chin et al., 1995, Lahoz et al., 1994, Roussel et al., 1996). 
Further, cells from mad1-/-, mxi1-/-, or mnt-/- mice showed increased proliferative 
capacity (Foley et al., 1998, Hurlin et al., 2003, Schreiber-Agus et al., 1998). The 
capacity of Mad to inhibit proliferation is tightly linked to its transcriptional 
function since Mad mutants that do not bind DNA, associate with Max, or contain 
a functional repression domain are inactive in biological assays. The effects of 
Mad on proliferation and differentiation can also be due to the ability of Mad to 
alter cell cycle. There are studies  that indicated Mad1 overexpression resulted in 
delayed G0 to S phase transition, G1 arrest or accumulation of cells in the G1 (or   30
G2) phase of the cell cycle, reduced CyclinE/Cdk2 activity and growth arrest at 
reduced cell density {Queva, 1999 #249; Bejarano, 2000 #250; Chen, 1995 #31; 
{Roussel, 1996 #313}(see Paper III).   
 
  It has been shown that c-Myc stimulates cell growth (defined as increase in cell 
mass and size) independent of cell cycle status in certain cell types such as B cells, 
hepatocytes, Drosophila wings and T cells (Iritani and Eisenman, 1999, Johnston 
et al., 1999, Schuhmacher et al., 1999). In Drosophila melanogaster loss of c-myc 
homolog dmyc results in delayed growth and reduced cell size (Johnston et al., 
1999). Overexpression of dmyc, on the other hand, gives rise to larger cells. Cell 
division rate of these cells is not affected neither by loss nor overexpression of 
dmyc indicating that distinct Myc activities control cell cycle and cell growth. For 
instance, primary B cells with overexpressed Myc are larger at every stage of their 
development (Iritani and Eisenman, 1999) supporting previous data. In addition, 
N-myc null progenitor cells from conditional knock-out mice show impaired 
proliferation, an increase of neuronal differentiation and changed morphology and 
size (Knoepfler et al., 2002). Several of Myc target genes are involved in 
metabolism. Some of these genes are believed to be involved in the control of 
molecular mechanism of cell growth. For instance, rate-limiting translation factors 
eEIF4 and eIF2α are among these genes. Mad genes are generally considered to 
have growth inhibitory effects. It has been reported that Mad1 reduces cell size in 
thymocytes (Iritani and Eisenman, 1999). It is however not clear if cell growth and 
cell cycle are coupled in cells with overexpressed Mad. Mad proteins and cell 
growth will be discussed in detail in Results and Discussion section. 
 
In addition to its positive regulatory effect of proliferation Myc often has a 
negative effect on differentiation. In several cell types, including neuroblastoma, 
myeloid cells, erythroleukemia cells and teratocarcinoma cells, Myc is 
downregulated during differentiation (Gonda and Metcalf, 1984, Lachman and 
Skoultchi, 1984, Thiele et al., 1985). Further, it has been shown in many of these 
cells that overexpression of Myc can inhibit differentiation (Coppola and Cole, 
1986, Freytag, 1988, Larsson et al., 1988). Myc can exert its inhibitory effect in 
differentiation for instance by repressing certain target genes important for 
differentiation process. It has been observed that Myc represses C/EBPα which is 
important in inducing differentiation of 3T3-L1 adipocytes (Mink et al., 1996). 
However, it has also been shown that differentiation of certain cell types is not 
inhibited, and in a number of cases even promoted by Myc (Gandarillas and Watt, 
1997, Lerga et al., 1999).  
 
  Mad is usually expressed in differentiating and/or growth arrested cells. Several 
studies has shown a clear correlation between terminal differentiation and 
increased mad-family mRNA levels. In hematopoietic cells both mad1 and mxi1 
transcripts and proteins are detected rapidly after induced differentiation (Ayer 
and Eisenman, 1993, Larsson et al., 1994, Zervos et al., 1993). The increase in 
Mad1 protein resulted in a switch from Myc:Max to Mad:Max complexes after 
induced differentiation (Ayer and Eisenman, 1993, Hurlin et al., 1995a, Larsson et 
al., 1997). This model is supported by the evidence that the occupancy of the 
target genes promoters, cyclin D2 and hTERT, in vivo shifts from Myc.Max 
toward Mad1:Max predominance during hematopoietic differentiation (Bouchard   31 
et al., 2001, Xu et al., 2001). In situ hybridization analyses of embroyonic tissues 
during mouse development indicate distinct but overlapping expression pattern of 
mad family RNAs in different tissues. (Hurlin et al., 1995a, Hurlin et al., 1995b, 
Vastrik et al., 1995). These studies confirmed that c-myc and N-myc is primarily 
expressed in proliferating cells. Both mxi1 and mad4 transcripts were detected at 
low levels in increasing cells but however their expression levels were increased 
in differentiating cells. mad1 gene was observed to be expressed in cells late in the 
differentiation whereas mad3 was expressed in the S-phase of the proliferating 
cells (Hurlin et al., 1995b, Pulverer et al., 2000, Queva et al., 1998). There are 
however also some contradictory results concerning mad1 and its function in 
differentiation. For instance, Mad1 has been shown to stimulate differentiation in 
mouse erythroleukemia (MEL) cells while it blocks differentiation of 3T3-L1 
adipoblasts (Cultraro et al., 1997b, Pulverer et al., 2000). Further it has been 
observed that granulocytic precursor cells of mad1
-/- mice have an abnormal cell 
cycle resulting in increased proliferation and delayed terminal differentiation 
(Foley et al., 1998). Recently it has also been suggested that during granulocytic 
differentiation Mad1 and p27 can cooperate and downregulate Myc. These results 
indicate that during differentiation of certain cell types Mad proteins might disrupt 
cell cycle progress (McArthur et al., 2002). For further discussion see Results and 
discussion section. 
 
A number of oncoproteins that stimulates proliferation such as Myc and E1A can 
also induce apoptosis. It has been shown that deregulated c-Myc expression 
sensitizes cells to a range of pro-apoptotic stimuli, such as DNA damage and 
hypoxia, and depleted survival factors, such as serum, IL-3. Myc can also 
potentiate apoptosis by sensitising cells to signalling through CD95, TNF and 
TRAIL (Hueber et al., 1997, Klefstrom et al., 1994, Lutz et al., 1998) Myc 
induced apoptosis has also been reported to involve activation of the 
Arf/Mdm2/p53 pathway (Zindy et al., 1998).Arf is upregulated by Myc resulting 
in accumulation of p53 which in turn can induce apoptotic effectors such as Bax. 
Myc has also been shown to repress anti-apoptotic factors such as Bcl2 and Bcl-x. 
These factors suppress apoptosis by blocking the membrane permabilization 
(MOMP) that is necessary for cytochrome C release (Martinou and Green, 2001). 
Not surprisingly Mad proteins has been shown to restrain apoptosis induced by 
various stimuli. For instance, targeted disruption of Mad1 has been observed to 
enhance the apoptosis of granulocytes upon cytokine withdrawal (Foley et al., 
1998). Apoptotic response to DNA damage and death receptor signalling has been 
shown to be impaired when Mad1 is overexpressed (Bejarano et al., 2000, 
Gehring et al., 2000).  
 
Neuroblastoma 
Neuroblastoma (NB) is a childhood tumour that originates from sympathetic 
neuroblasts of the peripheral nervous system. It is one of the most common solid 
tumors of childhood primarily affecting children under five years (the median age 
18 months). NB accounts for 7-10% of the childhood cancers (although 
compromising 15% of childhood cancer death) and approximately 10-15 children 
under the age of 15 are diagnosed in Sweden every year. The tumours are usually   32
located in the adrenal gland and sympathetic ganglia of the abdomen, neck, throax, 
and/or pelvis. Neuroblastomas most commonly spread to regional lymph nodes, 
bone and bone marrow. NB has broad clinical characteristics and patient outcome. 
The symptom of the disease differs depending on location of the tumour, 
metastatic spread and the age of the patient (for review see (Brodeur, 2003)).  
 
The clinical hallmark of neuroblastoma is its variability. It can vary from very 
benign, untreatable tumours to tumours that can differentiate spontaneously 
despite their metastatic spread. Spontaneous regression is an enigmatic clinical 
behaviour of NB that is particularly seen in infants. NB is classified into four 
stages according to the International Neuroblastoma Staging System (INSS) 
(Brodeur et al., 1993, Evans et al., 1971). This system is based on local growth of 
the tumour, growth of differentiation, local and distant infiltration and the age of 
the child at diagnosis (stage 4S tumours). A higher stage indicates a more 
advanced disease. Tumours of stage 1 show a localised growth pattern, while stage 
4 tumours display metastatic growth. Stage 4S can undergo spontaneous 
regression despite its colonalisation of several organs (infants under the age of 1 
year). In general, stages 1, 2 and 4S have a good prognosis with or without 
treatment, whereas stages 3 and 4 have a poor prognosis despite treatment. In 
addition, patients diagnosed under the age of two years usually have a better 
prognosis than older patients. The INSS have been a valuable tool in prediction of 
prognosis and choice of appropriate treatment method. Unnecessary treatments 
can be avoided using INSS. 
 
Recent years, various genetic and biological features in NB have been investigated 
to better understand the behaviour of NB and to find genetic markers which can 
improve the diagnosis/prognosis of the disease. Several tumour markers have been 
revealed including N-myc amplification, ploidy, deletion or loss of heterozygosity 
of chromosome
 1p and gain of chromosome 17q. Many genetic features of NB are 
correlated to the clinical outcome. For instance, N-myc amplification or allelic loss 
(such as 1p) is correlated with more aggressive tumours and poor prognosis, while 
near-triploidy is associated with better outcome (Bown et al., 1999, Brodeur, 
2003, Brodeur et al., 1984, Caron et al., 1996, Seeger et al., 1988). Amplification 
of N-myc was originally described in NB cell lines (Schwab et al., 1983) and 
shortly after in some neuroblastoma tumours (Brodeur et al., 1984) correlating 
with advanced tumours and poor prognosis. Occurrence of amplification of N-myc 
is 25% in NB and 40% in the advanced stages of NB (Brodeur, 2003, Kohl et al., 
1984, Schwab et al., 1984, Seeger et al., 1985). The reason why N-myc 
amplification is correlated to a more aggressive phenotype is still not known. 
There is corresponding overexpression of N-myc mRNA and protein (Seeger et 
al., 1988), which probably ensures through its target genes that cells stay in the 
cell cycle and not enter G0, and maintains cells at an immature stage (Nakagawara 
et al., 1992). N-myc amplification has strong correlation with loss of 1p 
heterozygosity (Fong et al., 1989). A large body of evidence shows the 
involvement of N-myc in NB development. For instance, the ectopic expression of 
N-Myc into neuroblastoma cells in culture leads to enhanced proliferative 
potential. Further, targeting N-myc to neuroectormal cells leads to development of 
NB in transgenic mice (Knoepfler et al., 2002, Thiele and Israel, 1988, Weiss et 
al., 1997). It has been shown that differentiation of N-myc amplified NB cell lines   33 
in vitro with RA, IFN-γ and TPA correlate with N-Myc downregulation 
(Hammerling et al., 1987, Thiele et al., 1985, Watanabe et al., 1989). Further it has 
also been observed that inhibition of N-Myc expression by antisence technology 
promote the inhibition of growth and a more differentiated phenotype (Schmidt et 
al., 1994).  
 
Cancer cells usually have increased telomerase activity. In neuroblastoma, 
telomerase activity has been shown to correlate inversely with patient outcome. 
There is also a direct correlation between high expression of telomerase and N-
myc amplification (Hiyama et al., 1995). Telomerase (hTERT) has been shown to 
be a direct target gene of c-Myc and N-Myc (Lutz et al., 1996, Mac et al., 2000, 
Wang et al., 1998a) Neurotrophins (NT) are growth factors that regulate growth, 
development, survival and repair of the nervous system. They can both bind the 
high-affinity tyrosine kinase receptors belonging to trk family and low-affinity 
p75
NTR receptor. The main ligands for the TrkA, TrkB and TrkC receptors are 
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and 
neurotrophin-3 (NT-3) respectively. TrkB can also interact with NT-4 
(Patapoutian and Reichardt, 2001). p75
NTR receptor bind all NT but the function of 
this receptor is still unclear. Activation of the TrkA receptor by NGF leads to 
survival and differentiation of neuroblasts into ganglion cells. TrkA is expressed 
in NB tumours with favourable prognosis and is inversely correlated to N-Myc 
expression, whereas TrkB is expressed mostly in tumours with poor prognosis and 
N-myc amplification (Brodeur, 2003).  
 
Neuroblastoma is conventionally treated by surgery, autologous bone marrow 
transplantation, radiation and chemotherapy. However, as the knowledge about 
important genes, proteins and pathways involved in pathology of neuroblastoma 
increases, it will probably lead to development of more biologically based 
therapies, such as differentiation therapy, induction of apoptosis and 
immunotherapy. Differentiation threapy is an approach that is promising in 
neuroblastoma since retinoic acid derivates have been shown to induce 
differentiation and decrease growth rate of neuroblastoma cells (Sidell et al., 1983, 
Thiele et al., 1985). In clinical trials, high-risk neuroblastoma patients have been 
treated with 13-cis retinoic acid after chemotherapy and bone marrow 
transplantation. A significantly increased survival rate with minimal toxicity was 
observed in this study (Matthay et al., 1999). 
 
In vitro models of neuronal differentiation 
Cell lines derived from tumours of the nervous system has been extensively used 
as model systems to study aspects of neuronal differentiation or biology of 
neuroblastoma. In murine systems, the rat pheochromocytoma cell line PC12 is the 
most frequently used for neuronal differentiation studies. There are several cell 
lines established from high-stage (mostly stage 3 and 4) human neuroblastoma 
tumours with N-myc amplification, such as frequently used IMR-32, LAN-2 and 
LAN-5 cell lines. Attempts to establish cell lines from low-stage tumours have not 
been so successful. One exception is the SH-SY5Y cell line with no N-myc 
amplification which is a well-established model for neuronal differentiation. SH-
SY5Y is a subclone of the SK-N-SH cell line that was established from the bone   34
marrow biopsy of a 4-year-old girl with metastatic neuroblastoma (Biedler et al., 
1973). The phorbol ester TPA, retinoic acid (RA) and certain growth factors are 
used to differentiate these cells. SH-SY5Y cells has been shown to differentiate 
and get growth arrested when treated with TPA and RA (Pahlman et al., 1981, 
Pahlman et al., 1984) (paper I). There are a number of characteristics of the 
differentiation process, such as extension of neurites and expression of certain 
neuronal differentiation markers. Growth-associated-protein-43 (GAP43), 
neuronal specific enolase (NSE), neuropeptide tyrosine (NPY) and choline 
acetyltransferase activity (ChAT) are among these markers (Pahlman et al., 1995). 
It has also been shown that neuroblastoma cell lines with amplified N-myc can 
differentiate to some extent in response to TPA, RA and IFN-γ (Haussler et al., 
1983, Montaldo et al., 1992, Parodi et al., 1989, Sidell, 1982, Spinelli et al., 1982, 
Watanabe et al., 1989) (Paper I). For instance, RA and IFN-γ has been observed to 
differentiate LAN-5 cells and lead to neurite outgrowth, inhibition of proliferation 
and increased levels of neurotransmitters (Sidell, 1982, Wuarin et al., 1991). 
 
In vitro models for myeloid differentiation 
Establishment of leukaemia and lymphoma cell lines have made important 
contributions to the studies of these types of cancer, but also to studies of 
hematopoiesis, haematology in general and immunology. Some of these cell lines, 
which are relevant to this thesis, are U-937, HL-60 and K-562 cells. The human 
monoblastic U-937 cells are established from a patient with histiocytic lymphoma 
and are arrested at the monocytic stage of the differentiation (Sundstrom and 
Nilsson, 1976). It is well-documented that these cells can be induced to undergo 
terminal differentiation along the monocytic lineage with differentiation agents 
such as TPA, RA and VitD3. This makes U-937 cells an excellent model system to 
study myeloid/monocytic differentiation  (Nilsson et al., 1981). Distinct agents 
give rise to different differentiation phenotypes (Larsson et al., 1988, Oberg et al., 
1993, Olsson et al., 1983, Olsson and Breitman, 1982). The common 
characteristics for terminal differentiation of U-937 cells by these agents are 
growth arrest in G0/G1, increased expression of monocytic differentiation marker 
CD11c associated with β1 integrins and mature monocyte and macrophage 
morphology. The human HL-60 cell line is established from a patient with acute 
myeloid leukaemia (Collins et al., 1977), is bipotential and carry amplified c-myc 
gene. HL-60 cells, arrested at an early stage of myeloid differentiation, can be 
induced to differentiatiate by RA, TPA or DMSO treatment (Collins and 
Dorshkind, 1987). K-562 cells are established from a patient with chronic myeloid 
leukemia (CML) in blast crisis. K562 is frequently used as model system for 
studies of erythroid and megakaryocytic differentiation. 
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Aims of the present investigation 
The general objective of this thesis was to gain more knowledge about the role of 
Myc/Max/Mad-network proteins in the control of growth and differentiation of 
human neuronal and hematopoietic tumour cells. Since deregulation of myc-family 
genes is frequently observed in these types of human cancers, an import aim is to 
identify signals that negatively regulate Myc function, and which potentially may 
contribute to novel therapeutic strategies for treatment of such cancers.  
The thesis can be divided into three parts. The first part (Paper I and II) is based 
on previous results from hematopoietic cells demonstrating that IFN-γ can restore 
induced terminal differentiation and growth arrest in v-Myc-transformed human 
monoblasts despite continuous v-Myc expression. The aim of this part was to 
clarify whether IFN-γ when combined with differentiation signals could restore 
terminal differentiation and growth arrest also in N-myc-amplified human 
neuroblastoma cells, and if so whether the effects of the combinational therapy 
were due to regulation of Myc/Max/Mad-network proteins. In Part II (Paper III) 
the biological role of Mad1 during differentiation and growth inhibition in 
hematopoietic cells was investigated. The aim of the last part was to shed light on 
the ability of c-Myc to block hematopoietic differentiation and how this relates to 
its function to repress transcription. Since the mechanism by which Myc represses 
transcription is poorly understood, another objective in this part of the work was to 
gain more knowledge about this process. 
 
Specific aims:   
1.   To determine whether IFN-γ in combination with RA or TPA would have    
      synergistic effects in inducing differentiation and/or growth arrest in N-myc  
      amplified neuroblastoma cells. (Paper I) 
 
2.  To clarify whether induced neuronal differentiation of human neuroblastoma 
cells, with or without amplified N-myc, involves regulation of Myc/Max/Mad 
network proteins (Paper II) 
 
3.   To shed light on the role of Mad1 during differentiation and growth arrest in  
    human hematopoietic cells (Paper III) 
 
4. To determine whether the ability of Myc to block hematopoietic 
differentiation involves repression of transcription of cyclin-dependent kinase 
inhibitors such as p21Cip1 and to reveal the mechanism behind such 
transcriptional repression by Myc (Paper IV) 
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Results and Discussion 
Interferon-γ cooperates with retinoic acid and phorbol ester to 
induce differentiation and growth inhibition of human 
neuroblastoma cells (Paper I) 
Advanced stages of neuroblastoma exhibit amplifications of N-myc at 30-40% of 
the cases and is correlated to poor prognosis despite therapy. These circumstances 
necessitate new approaches for therapy. It has previously been shown that 
neuroblastoma cells, including cells with N-myc amplification, treated with 
differentiation agents such as retinoic acid (RA), phorbol ester (TPA) and IFNs in 
vitro undergo cellular differentiation and stop to divide (Haussler et al., 1983, 
Pahlman et al., 1981, Pahlman et al., 1984, Parodi et al., 1989, Sidell, 1982, 
Spinelli et al., 1982, Watanabe et al., 1989). In clinics ‘differentiation therapy’ 
with RA has been used after autologous bone barrow transplantation with 
encouraging results. We investigated here the possibility to improve differentiation 
therapy by combining agents known to induce differentiation of neuroblastoma 
cells in vitro. Our group has earlier shown that combination of RA or TPA with 
IFN-γ will overcome the Myc induced growth arrest and differentiation in 
monoblastic U-937 despite continuous expression of v-Myc protein (Bahram et 
al., 1999, Oberg et al., 1991). Further, in previous studies RA and IFN-γ has been 
shown to have synergistic effects on differentiation and cell growth in LAN-5 
cells (Cornaglia-Ferraris et al., 1992, Wada et al., 1997, Wuarin et al., 1991). 
Therefore we chose to combine IFN-γ with RA and TPA to study their effects on 
cell growth and differentiation in neuroblastoma cells. The aim of this study was 
to investigate if the synergistic effects of IFN-γ and RA could be observed in other 
neuroblastoma cell lines than LAN-5 and also if IFN-γ synergize with TPA. 
 
  In our study we utilized 5 neuroblastoma cell lines with (LAN-1, LAN-2, LAN-
5 and IMR-32) or without (SH-SY5Y) N-myc amplification. These cell lines were 
subjected to substances RA, TPA, IFN-γ alone or in combination. The effects of 
these treatments on proliferation and viability were determined by cell counting. 
Differentiation was evaluated by morphology changes, by measurement of neurite 
length and number, and by studying the expression of neurofilaments as a marker 
of neuronal differentiation. 
 
  Our results showed that RA induced differentiation to various extents in all cell 
lines studied. The most prominent effect was seen in SH-SY5Y cells which lack 
N-myc amplification. Further, RA had also growth inhibitory effects in all cell 
lines treated. In cell lines LAN-1 and LAN-2 lower cell viability might have 
contributed to growth inhibitory effects. RA in combination with IFN-γ enhanced 
differentiation and/or growth inhibition in all five cell lines, but particularly in cell 
lines with elevated N-Myc expression. Enhanced differentiation was observed as 
increased percentage of differentiated cells and increased length of neurites. 
Complete growth inhibition was seen in LAN-5, IMR-32 and LAN-1 containing 
N-myc amplification after 2-4 days of RA+IFN-γ treatment. LAN-2 cells, which 
express much less N-myc mRNA despite amplification and SH-SY5Y cells with   37 
normal N-myc alleles, responded to RA treatment effectively by decrease in cell 
number. Addition of IFN-γ enhanced the effect to some extent.  
 
  TPA affected differentiation and growth to different degrees in cell lines 
included in the study. In SH-SY5Y cells, TPA had strong effects on proliferation 
and differentiation in agreement with previous reports (Pahlman et al., 1981, 
Pahlman et al., 1984, Spinelli et al., 1982). LAN-1 and LAN-5 cells were growth 
inhibited to a lesser extent and LAN-2, IMR-32 cells were only affected poorly. 
TPA had poor or none effect on differentiation of these four cell lines. 
Combination of TPA with IFN-γ led to enhanced growth inhibition in various 
degrees in all cell lines. LAN-5 and IMR-32 cells, with high N-Myc levels, 
responded strongest to TPA+IFN-γ treatment. The viability of IMR-32 cells was 
somewhat lower and this might have contributed to the inhibitory growth effects. 
TPA+IFN-γ had pronounced effects on differentiation in all cell lines but LAN-2.  
Percentage of differentiated cells and neurite length were increased in LAN-1, 
LAN-5, IMR-32 and SH-SY5Y cells. Further, expression of neurofilament in 
LAN-5 and IMR-32 after TPA, IFN-γ or TPA+IFN-γ supported data on 
proliferation and differentiation suggesting that TPA+IFN-γ stronger effects than 
the either agent alone.  
 
 IFN-γ alone induced differentiation to some extent in all five cell lines but the 
strongest effects were seen in LAN-1 and SH-SY5Y cells. Growth inhibition was 
observed after IFN-γ induction in cell lines LAN-5 and SH-SY5Y and to a lesser 
extent in IMR-32 cells. 
 
  In summary, the combined treatments RA+IFN-γ or TPA+IFN-γ had synergistic 
or enhancing effects on morphological differentiation, neurite outgrowth and 
proliferation in all cell lines, in particular in cell lines with amplified N-myc. 
Single agent treatment were mostly effective in SH-SY5Y cells lacking N-myc 
amplification. These results may be of potential interest for the development of 
combinational differentiation therapy in the treatment of high risk neuroblastoma. 
 
Mad 1 is upregulated of during human neuronal differentiation 
(Paper II) 
The expression of the mad-family genes is regulated during development and 
differentiation of a variety of cell types as discussed above, including neuronal 
cells (Ayer and Eisenman, 1993, Hurlin et al., 1995a, Hurlin et al., 1995b, Queva 
et al., 1998, Vastrik et al., 1995). For instance, high expression of mad1 and mad4 
is observed in differentiated cells during murine neural tube development, whereas 
mxi1, mad3 and mnt are coexpressed with N-myc in proliferating cells undergoing 
differentiation (Hurlin et al., 1997, Hurlin et al., 1995b). Expression of mxi1 and 
mnt can also be found in more differentiated cells. Little is however known about 
Mad family expression during human neuronal differentiation. 
 
  To study the expression of mad/mnt family genes and proteins during human 
neuronal differentiation, we made use of the SH-SY5Ycell line, which is a widely 
used model system for various studies of symphatetic neuronal cells (Pahlman et 
al., 1981, Pahlman et al., 1983). We first investigated the expression patterns of 
mad1, mxi1, mad3, mad4, mnt, max, c-myc and N-myc mRNA during TPA-  38
induced SH-SY5Y differentiation by northern blot analysis. Increased expression 
of mad1 mRNA was detected already after one hour of TPA treatment while the 
low expression of c-myc declined, but expression of the other genes were either 
unchanged (mxi1, mnt, max), or too weak to be detected (mad3, mad4, N-myc)  
 To study the corresponding proteins during the differentiation process 
immunoprecipitations of lysates from 
35S-methionine in vivo labelled cells were 
performed. The synthesis of Mad1 began to increase after 1 hour and reached a 
peak after 4 hours. A decrease in Mad1 to pre-induction levels was observed after 
24 hours of TPA induction with a subsequent upregulation again at 48 and 96 
hours demonstrating a biphasic expression pattern. The expression of mad1 
mRNA exhibited a similar kinetic pattern. This biphasic expression pattern was 
also observed in another neuroblastoma cell line, SK-N-BE, in a recent study by 
Smith et al (Smith et al., 2004) and as well as in murine erytroleukemia (MEL) 
cells (Cultraro et al., 1997b). The myeloid and keratinocyte in vitro differentiation 
system also exhibit an early upregulation of Mad1 but unlike the cell lines 
mentioned above they do not exhibit a biphasic pattern of Mad1 expression. The 
differences in the Mad1 kinetics indicate that the regulation of Mad1 expression is 
complex and that various differentiation signals might act on mad1 promoter. In 
addition, differences in cell type and level of differentiation may also contribute to 
the dissimilarities.  
 
  c-Myc protein synthesis did also display a biphasic expression pattern. Max 
protein levels remained constant during the first 24 hrs of TPA induction and 
increased a little bit at later time points. The expression level of Mad1 was lower 
than U-937 myelomonocytic cells used as reference. Since c-Myc levels were also 
low the upregulation of Mad1 might still be enough to cause a switch from c-
Myc:Max to Mad1:Max heterodimers on c-Myc/Mad1 target genes. 
Unfortunately, we did not posses antibodies of high enough quality to analyse 
other Mad/Mnt-family proteins. N-Myc was not detectable in these cells. 
 
  In summary, the expression of Mad1 is upregulated and c-Myc downregulated 
in SH-SY5Y cells during TPA induced differentiation. This result thus resembles 
the expression of mad1 in differentiated murine neuornal cells as described above 
and indicates a switch towards Mad1 predominance in Myc/Max/Mad network, 
preceding differentiation and growth arrest of human neuronal cells.  
 
 
Regulation of the Myc/Max/Mad network in human 
neuroblastoma cells with N-myc amplification using IFN-γ 
together with RA or TPA (Paper I and II)  
  In paper I we demonstrate that IFN-γ can synergize with RA or TPA to enhance 
differentiation and growth arrest in a number of neuroblastoma cell lines, in 
particular in cell lines with amplified N-myc. It was therefore of interest to 
investigate mechanisms involved in the effects of IFN-γ and whether a shift in the 
N-Myc/Mad1 expression pattern would correlate with IFN-γ enhanced 
differentiation and growth arrest in these cells. We utilized the N-myc amplified 
cell lines IMR-32 and LAN-5 for these studies. The cells were treated with RA, 
TPA, IFN-γ alone or in combination, for three days. The protein expression of   39 
Mad1, N-Myc and Max was studied by immunoprecipitations of 
35S-methionine 
labelled cell lysates.  
 
  In contrast to non-N-myc amplified SH-SY5Y cells, Mad1 was only upregulated 
weakly in IMR-32 and even less in LAN-5 cells after TPA treatment. Combination 
of TPA with IFN-γ led to a strong upregulation of Mad1 in LAN-5 cells and to a 
lesser degree in IMR-32 cells. This was correlated with synergistic effects of 
TPA+IFN-γ on differentiation and growth inhibition. N-Myc protein levels were 
not at all or weakly reduced after TPA or TPA+IFNγ treatment.  
 RA+IFN-γ treatment did also increase Mad1 expression levels, although not to 
the same extent as TPA+IFNγ but on the other hand, led to a downregulation of N-
Myc levels in both cell lines. Reduced N-Myc expression was in good agreement 
with downregulated N-myc mRNA expression in LA-N-5 cells (Wada et al., 
1997). Treatment with RA alone had less effect on the expression of N-Myc, 
approximately 2-fold reduction or less in repeated experiments in both cell lines.  
 
  In conclusion, the cooperative effect of TPA and IFN-γ on differentiation and 
growth arrest correlated with increased Mad1 protein levels. The similar 
synergistic effects of RA and IFN-γ primarily correlated with decreased N-Myc 
levels. This suggests that different signals affect the Myc/Max/Mad network in 
distinct ways but with similar outcomes. 
 
 
IFN-γ costimulation results in reduced N-Myc/Max complex 
formation and Mad1/Max predominance at ODC promoter 
(Paper II) 
It has earlier been reported that cellular concentration of Max containing 
complexes shifts from c-Myc/Max to Mad1/Max predominance during induced 
differentiation of hematopoietic cells and keratinocytes (Ayer and Eisenman, 
1993, Hurlin et al., 1995a, Larsson et al., 1997) resulting in preferential Mad1 
occupancy of the cyclin D2 and hTERT target gene promoters (Bouchard et al., 
2001, Xu et al., 2001). 
 
  We performed coimmunoprecipitations of N-Myc/Max complexes from IMR-32 
cell extracts followed by western blot analysis to study whether the cellular 
amounts of N-Myc:Max heterodimers were changed in response to TPA, RA and 
IFN-γ or their combinations in N-myc-amplified neuroblastoma cells. Slight 
reductions in N-Myc/Max complexes were observed after RA, TPA and IFN-γ 
treatments. The combined treatments of RA+IFN-γ and TPA+IFN-γ, on the other 
hand, resulted in considerable reductions in the concentrations of N-Myc/Max 
heterodimers. This reduction in the case of RA+IFN-γ seem in part to be due to 
decreased N-Myc protein expression and partially due to posttranslational effects 
on N-Myc:Max complex formation and/or complex stability. In the case of 
TPA+IFN-γ posttranslational effects seem to predominate. Therefore, the 
phenotypic changes in response to combinational treatments are likely not only 
due to changed Mad1 and N-Myc expression. Similar results were reported in v-
Myc transformed U-937 monoblasts, where IFN–γ in combination with TPA   40
inhibited v-Myc activity rather than affecting the v-myc expression (Bahram et al., 
1999). 
 
  Further, we asked whether occupancy of N-Myc, Max and Mad1 on the N-Myc 
and Mad target gene ODC promoter will also shift towards Mad1 predominance. 
We performed ChIP assays using undifferentiated and RA+IFN- γ differentiated 
IMR-32 cells. A dramatic decrease in N-Myc occupancy was observed, while 
Mad1 binding increased in differentiated cells. The presence of Max was 
essentially unchanged after RA+IFN-γ treatment. In addition, RA+IFN-γ induced 
differentiation led to decreased acetylation of histone H4 indicating alteration of 
the chromatin structure into a more condensed state.  
 
  In summary, these results suggest that IFN-γ in combination with RA or TPA 
regulates the expression of N-Myc and/or Mad1 resulting in a shift in balance 
towards Mad1/Max heterodimers. Mad1/Max occupy target gene promoters which 
results in altered chromation structure and transcriptional repression, correlating 
with terminal differentaion and growth arrest. It is possible that also other factors 
can also be regulated and cooperate with Mad1 in inducing differentiation and 
inhibiting growth, such as p21
Cip1 and p27
Kip1. p21
Cip1 has been shown to be 
regulated by IFN–γ via the JAK-STAT pathway (Chin et al., 1996). RA treatment 
of neuroblastoma and hematopoeitic cells has lead to upregulation of both p21
Cip1 
and p27
Kip1 (Borriello et al., 2000, Jiang et al., 1994, Liu et al., 1996). TPA has 
also been shown to induce p21
Cip1/Waf1 (Biggs et al., 1996, Blagosklonny et al., 
1997, Jiang et al., 1994, Zeng and el-Deiry, 1996). 
 
  Our obtained results with the neuroblastoma cells with N-myc-amplification 
suggest that combined RA+IFN-γ “differentiation therapy” potentially may be of 
clinical interest in treatment of advanced stages of childhood neuroblastoma. 
 
 
Mad1 inhibits cell growth and proliferation but does not 
promote differentiation or overall survival in human U-937 
monoblasts (Paper III) 
Mad is usually expressed in differentiating and/or growth arrested cells as 
mentioned earlier. Utilizing U-937 monocytic differentiation model system we and 
others have previously shown that Mad1 is rapidly induced during RA, TPA and 
vitamin D3 (VitD3) induced differentiation. The biological role of Mad1 during 
differentiation and growth inhibition is, however, not well understood. The aim of 
this study was to shed light on this role by investigating the effects of ectopic 
expression of Mad1 during these processes.  
 
  For these studies, we established U-937-1 clones with stable integration of 
inducible Mad1 constructs by using the tet-activator and lac-repressor systems. 
This tet-on system (Gossen et al., 1995) was regulated by the rtTA-activating 
ligand doxycycline (Dox). The clones were studied with regards to proliferative 
capacity, differentiation and cell cycle distribution. The question asked here was 
whether Mad1 expression would be enough to induce growth inhibition and 
differentiation in the absence of differentiation signals, alternatively whether it 
would enhance differentiation induced by these signals.     41 
 
  First, a number of clones were selected and mad1 mRNA and protein levels 
were studied by northern blot analysis and by immunoprecipitation of 35S-
methionine labelled cell lysates with Mad1 antibodies, respectively. The clones 
exhibited various basal and inducible Mad1 levels. Kinetic analysis revealed that 
Mad1 expression was upregulated after 6 hours of Dox treatment and the protein 
levels remained stable at least 48 hours after induction. Coimmunoprecipitations 
showed that increased levels of Mad1 correlated with increased levels of 
Mad1/Max heterodimers. In a control clone containing the luciferase gene instead 
of mad1 the endogenous amount of Mad1 in complex with Max was very low. 
Further, we studied whether the elevated basal level and/or the Dox-induced 
expression of Mad1 affected the expression of Myc/Mad target gene ODC by 
realtime RT-PCR. Our results showed that induction of Mad1 led to reduced 
expression of ODC. Taken together, these results indicate that our inducible 
system was working and that exogenous Mad1 proteins were active and had a 
functional role. 
 
  We next investigated the proliferative potential of Mad1-expressing U-937 cells 
and found that it was substantially lower than U-937 control cells. Mad1 clones 
also formed fewer colonies on semi-solid medium. Addition of Dox only partially 
enhanced this effect indicating that elevated basal expression of Mad1 may have 
exceeded a threshold level effecting proliferation. A mutant clone which lack NH2 
terminus of Mad1 containing SID domain did not exhibit reduced proliferative 
capacity suggesting that NH2 terminus of Mad1 is required for the 
antiproliferative action in agreement with previous reports (Grandori et al., 2000). 
Cell cycle analysis showed that the Mad1-clones exhibit an increased number of 
cells in the G1 phase of the cell cycle. Addition of nocodazole to block cells in 
G2/M phase showed that the Mad1 expressing clones contained a larger 
subpopulation of cells arrested in G1 than the control clone. The majority of the 
Mad1 cells continued to cycle until the nocodazole block G2. These results agree 
with the results suggesting that Mad1 increases the probability of cells to arrest in 
(or exit cell cycle at) G1 rather than affecting duration of the cell cycle (Holzel et 
al., 2001). In summary, our results indicate that Mad1 has growth inhibitory 
effects supporting previous data. 
 
  Both Myc and Mad have been shown to affect cell size. In certain but not all 
cellular settings, Myc seems to stimulate cell growth independent of the cell cycle 
whereas Mad1 has been reported to reduce cell size in thymocytes (Iritani et al., 
2002, Iritani and Eisenman, 1999, Johnston et al., 1999, Schuhmacher et al., 
1999). Our results show that Mad1-expressing cells are smaller than control cells 
in all phases of the cell cycle and this difference is particularly pronounced in RA 
differentiated cells. The reason why Myc and Mad affect cell size independent of 
cell cycle phase in some but not all cellular settings is not clear but may reflect 
variations in the link between cell growth and cell cycle control in different cells.  
 
  We next investigated whether induced Mad1 expression could affect the stage of 
differentiation or the capacity to differentiate. The state of differentiation was 
determined by measuring CD11c and CD14, surface antigens specific for 
monocyte differentiation, by flow cytometry at different time points after addition 
of Dox. No significant change was detected in the expression of surface antigens   42
on Mad1-containing clones compared to control clones both in presence and 
absence of Dox treatment. This suggests that Mad1 expression can not result in 
spontaneous differentiation of U-937 cells. Further, no enhancing effects of Mad1 
on differentiation induced by RA, TPA or VitD3 could be observed. In contrast, 
the RA induced differentiation was rather inhibited (indicated by a lower 
percentage of cells expressing CD11c) in Mad1-containing clones at day 1 and 3 
after induction. However, by 5 days, the percentage of CD11c expressing cells 
was approximately the same as in the control cells suggesting that RA-induced 
differentiation was delayed in Mad1-expressing cells. The mutant Mad1 clone, 
lacking SID containing NH2 terminal part of Mad1, did not exhibit the delay 
suggesting that interaction of Mad1 with the Sin3 transcriptional repressor 
complex is required for this process to take place.  
Our results contrast to the data from Cultraro et al. (Cultraro et al., 1997a) which 
suggest that enforced Mad1 expression induces differentiation of MEL cells. On 
the other hand, our results agree with results from Pulverer et al. (Pulverer et al., 
2000) suggesting inhibitory effects of Mad1 on adipocyte differentiation. This 
discrepancy may have several explanations. The two reports mentioned above and 
our results all agree on Mad1 as a growth inhibitor. The antiproliferative effect of 
Mad1 might effect differentiation in different ways depending on cell type and in 
some cases acting indirectly. Usually, differentiation and proliferation are well-
matched at earlier stages but in conflict at later stages of differentiation. For 
example, U-937 cells keep proliferating during the first days of RA-induced 
differentiation before arresting in G1 phase of the cell cycle. Mad1-expressing U-
937 cells on the other hand stop proliferating prematurely and exhibit reduced size 
in response to RA, correlating to delayed differentiation. Mad1 seem to interfere 
with the proliferative burst at the early stage of differentiation which seems to be 
necessary for the continuous differentiation. In addition, some growth inhibitory 
signals for U-937 cells, such as transforming growth factor β (TGF-β) that induce 
Mad1 expression, can inhibit differentiation (Oberg et al., 2001).  
 
  We also investigated whether Mad1 expression favours or disfavours apoptosis, 
since there are conflicting results regarding this in the literature. The cells were 
treated with TNF-α or CD95-Fas, well-known inducers of apoptosis, and the 
percentage of apoptotic cells was measured by Annexin V staining. TNF-α 
sensitized the Mad1-expressing cells to apoptosis whereas α-Fas did not but rather 
desensitized the cells to some extent. The increase in TNF-α sensitivity was not 
observed in a Mad1 mutant clone lacking the N-terminus of Mad1 containing the 
SID domain, suggesting that it involved Mad1-induced repression of target genes. 
Mad1 induced desensitisation by Fas-induced apoptosis also required the SID 
domain. The mechanism by which Mad1 sensitizes U-937 cells to TNF-α induced 
apoptosis is still unknown. Both Fas and TNF-α utilize a common signalling 
pathway to induce apoptosis involving FADD/caspase 8 and 10. It has been 
reported that Mad1-induced inhibition of Fas-induced apoptosis in osteosarcoma 
cells correlated with reduced levels of caspase activity (Gehring et al., 2000). 
TNF-α receptor signalling is much more complex than Fas-signaling since it both 
involves pro- (FADD/caspase 8 and 10) and anti-apoptotic (TRAF2/RIP1/NFκB) 
pathways (Nilsson and Cleveland, 2003, Varfolomeev and Ashkenazi, 2004). In 
addition, TNF-α also activates c-jun NH2-terminal kinase (JNK) pathway which   43 
exhibit both pro- and anti-apoptotic abilities. Since in our system, Mad1 sensitized 
TNF-α-induced apoptosis but not Fas-induced apoptosis, this might indicate that 
Mad1 inhibits the antiapoptotic NFκB pathway or enhances the proapoptotic JNK 
pathway. This hypothesis needs to be investigated further. 
 
  In conclusion, our results suggest that enforced expression of Mad1 in U-937 
cells inhibits cell growth and proliferation but does not promote differentiation or 
survival in general. The effects of Mad1 in differentiation and apoptosis seem to 
be more complex and necessitate further investigation. 
 
 
Myc represses differentiation-induced p21Cip1 expression via 
Miz-1-dependent interaction with the p21 core promoter       
(Paper IV)  
One of the well-known biological activities for c-Myc family proteins is its block 
of cellular differentiation. The mechanism behind this is however not well 
understood. The expression of c-Myc is generally downregulated in response to 
differentiating signals (Oster et al., 2002). Our group has earlier shown that 
constitutive expression of v-Myc blocks induced differentiation and growth arrest 
of human U-937 cells (Bahram et al., 1999, Larsson et al., 1988). The question we 
asked here was how c-Myc is involved in the block of differentiation. p21
Cip1 is 
rapidly induced in hematopoietic cell lines, including U-937 cells (Liu et al., 
1996), after treatment with differentiating agents and is believed to be an 
important component of the cellular growth/differentiation switch. We therefore 
hypothesized that v-Myc might interfere with the expression of p21 to block 
differentiation. As mentioned earlier p21
Cip1 belongs to Cip/Kip family of Cdk 
inhibitors and plays an important role in cell cycle arrest, differentiation, DNA 
repair, cell senescence and apoptosis (Sherr and Roberts, 1999, Steinman, 2002). 
 
  The ability of TPA to induce differentiation and growth arrest in U-937-1 and v-
Myc transformed U-937-myc6 cells were determined by measuring expression of 
the differentiation marker CD11c and by the incorporation of 
3H-labeled 
thymidine, respectively. U-937-1 cells differentiated as aspected, exhibiting 
increased expression of CD11c and reduced incorporation of 
3H-labeled 
thymidine. The v-Myc-expressing U-937-myc6 cells on the other hand showed no 
induction of CD11c and almost no reduction of 
3H-labeled thymidine indicating 
that differentiation and growth inhibition by TPA were blocked by v-Myc, in 
agreement with previous report (Larsson et al., 1988). We next asked if the 
expression of p21
Cip1 in response to TPA was altered in the v-Myc expressing 
cells. In U-937-1 cells p21
Cip1 mRNA and protein are detected after 4 hours post-
induction whereas no induction at all could be seen in the U-937-myc6 cells. c-
Myc levels declined as p21
Cip1 levels increased in both cell lines, whereas v-Myc 
levels was unaltered in U-937-myc6 cells. These results suggest that v-Myc 
directly or indirectly repress TPA-induced expression of p21
Cip1.  
 
  Next, we utilized transient transfection assays to investigate whether Myc can 
repress the p21
Cip1 promoter. U-937 cells were transfected with a full length p21 
promoter/reporter construct (0-luc) together with increasing amounts of c-Myc.   44
Both in absence or presence of TPA, coexpression of c-Myc led to a repression of 
reporter activity already at low levels of c-Myc suggesting that c-Myc affects 
p21
Cip1 expression at least partially at the level of transcription. A number of 
p21
Cip1 deletion mutants were utilized to map the Myc-responsive region of the 
p21
Cip1 promoter. Our analysis showed that deletions of sequences -2326 bp to -94 
bp relative to the p21
Cip1 start site did not abolish the ability of c-Myc to repress 
basal- and TPA-dependent transcription of p21
Cip1 expression. To further map c-
Myc responsive region two exchange mutants were generated by replacing either 
nucleotides -94/-50 of the p21 promoter (generating CMV/p21Luc) or nucleotides 
-49/+16 with the corresponding region of CMV promoter (generating 
p21/CMVLuc). c-Myc was unable to repress the activity of p21/CMVLuc 
indicating that the c-Myc responsive region is situated between -49 and +16 of the 
p21 core promoter. This also suggest that the four Sp1/3 binding sites located in 
the upper region of the promoter, which has previously been shown to be required 
for p21 induction by multiple signals (Gartel and Tyner, 1999), is not essential for 
the repressing effect of c-Myc. Further, to map domains of c-Myc required for 
repression a panel of c-Myc deletion mutants were used. We found that deletion of 
conserved HLH, Zip and MBII domains abolished the ability of c-Myc to mediate 
repression whereas deletion of the basic domain did not affect the transcriptional 
repressing indicating that direct binding of c-Myc to DNA is not required. 
 
  The HLH domain of c-Myc interacts with the initiator (Inr) binding transcription 
factor Miz-1 (Peukert et al., 1997) which has been shown to bind p15Ink4b at the 
core promoter (Peukert et al., 1997, Seoane et al., 2001, Staller et al., 2001). Since 
we had observed that HLH domain of c-Myc was involved in repression of p21 
promoter, we investigated the possibility that c-Myc exerts its repressive function 
through Miz-1. Using transient transfection and luciferase assays we studied 
ability of Miz-1 to activate p21 promoter. We observed that Miz-1 activated p21 
via the same core promoter region as c-Myc utilizes in repression. Three potential 
Miz-1 binding sites in this region of the promoter were identified and mutations of 
these sites eliminated most of the activating effect of Miz-1 suggesting that Miz-1 
act through these sites. When c-Myc was cotransfected it inhibited Miz-1-
dependent transcription in a dose dependent manner in both TPA treated and 
untreated cells. Further to investigate whether Miz-1 could be involved in 
differentiation processes, the expression of Miz-1 was studied. Miz-1 mRNA and 
protein were upregulated during differentiation in several myeloid cell lines, 
whereas c-Myc was downregulated as expected. 
 
  To investigate whether Miz-1 and c-Myc are able to bind the p21 core promoter 
in vitro, DNA oligo pulldown assays were utilized. Miz-1- and/or c-Myc- 
transfected Cos7 cells were precipitated with a double stranded oligonucleotide 
representing nucleotides -49 to +16 of the p21 promoter. Our results showed that 
Miz-1 alone bound to the promoter whereas c-Myc could not bind on its own. 
Once c-Myc was cotransfected with Miz-1 it could interact with the promoter 
indicating that c-Myc bind p21 promoter through Miz-1 interaction. Interestingly, 
we also observed that Miz-1 DNA binding was enhanced when cotransfected with 
c-Myc suggesting that c-Myc might stabilize the DNA binding of Miz-1. The 
dependence of c-Myc on Miz-1 for DNA binding was further demonstrated in this 
assay by using a c-Myc HLH point mutant, MycV394D, with impaired binding to   45 
Miz-1 but normal binding to Max (Herold et al., 2002). The mutant MycV394D 
showed a reduction both in Miz-1 and DNA binding to approximately 25-30% of 
that of wt c-Myc. Another mutant, Myc(BR)-Mad, where the HLHZip domain is 
replaced by the corresponding region in Mad1, is unable to bind Miz-1 but binds 
to Max and activates transcription from E-boxes (Staller et al., 2001). Unlike 
wildtype c-Myc, this mutant and MycV394D was unable to repress transcription 
of the p21 core promoter. Further, to demonstrate that repression of the 
endogenous p21 gene by Myc was Miz-1 dependent we utilized K562 leukaemia 
cells containing a Zn
2+ inducible wt c-Myc or MycV394D genes. TPA induced 
endogenous p21 expression was repressed by wt c-Myc but not by the mutant 
confirming the results from the p21 promoter/reporter assay. Next, we used 
chromatin immunoprecipitation (ChIP) assay to study whether c-Myc and Miz-1 
interact with the p21 promoter also in vivo. This analysis indeed showed presence 
of c-Myc, Miz-1 and Max on the p21 promoter. In addition, the analysis also 
demonstrated that the association of c-Myc with the p21 promoter was reduced 
after TPA-induced differentiation of HL-60 cells while the binding of Max and 
Miz-1 was only slightly affected. On the other hand, binding of v-Myc, Miz-1 and 
Max to p21 promoter increased after TPA treatment in v-Myc transformed cells, 
correlating with the expression of p21. 
 
  Taken together our results suggest that c-Myc represses both differentiation 
induced and basal p21 expression at least partially at the level of transcription. 
This is in agreement with previous reports suggesting that c-Myc inhibits both 
basal and TGF- -, TPA-, and p53-induced p21 expression in other cell lines 
(Ceballos et al., 2000, Claassen and Hann, 2000, Coller et al., 2000, Gartel et al., 
2001, Mitchell and El-Deiry, 1999). Our results further suggest that the Myc-
responsive region on p21 promoter is located around the transcriptional start site 
and that c-Myc binds this region via interaction with Miz-1, which associates 
directly with the p21 promoter. It has earlier been shown that c-Myc also utilizes 
Miz-1 for repression at the p15
INK4B promoter (Seoane et al., 2001, Staller et al., 
2001). We could also show that repression of the endogenous p21 gene depends 
on sites specifically interacting with Miz-1 by using mutants of c-Myc that are 
unable to bind Miz-1. 
 
 
c-Myc/Miz-1 functions as a growth/differentiation switch   
(Paper IV) 
The mechanism through which Myc represses transcription is not well understood. 
However, different models have been proposed on how c-Myc might mediate this 
process (for review see (Wanzel et al., 2003)). One of these models is that c-Myc 
activates the synthesis of transcriptional repressor proteins and in this way acts 
indirectly to repress genes. Another suggested model is that the Myc/Max 
heterodimer represses transcription by direct DNA-binding to E-boxes. However, 
so far Myc/Max dimers have not been found to interact directly to core promoters 
of repressed genes in vivo. It has also been suggested that c-Myc might sequester a 
necessary component of the basal transcription machinery by binding to the TFIID 
subunit TBP and thereby interfere with the preinitiation complex via an active repression mechanism (Facchini and Penn, 1998). The interaction of c-Myc with 
activators, such as Smads, Sp1 or NFY, might prevent their activation and lead to 
repression thereby (Gartel and Shchors, 2003). Another possibility is that Myc is 
recruited to the core promoters by protein-protein interactions, for example, Inr-
binding proteins, such as TFI-II, YY1, Miz-1 and Sp1 (Gartel et al., 2001, Peukert 
et al., 1997, Roy et al., 1993, Shrivastava et al., 1993).  
 
  Our results are in agreement with the model suggesting recruitment of c-Myc to 
the promoter by protein-protein interactions. Based on our results we suggest a 
model there Miz-1 plays a dual role (figure 5). Miz-1 can act as an activator of the  
Figure 5: A Myc/Miz-1 switch model for regulation of p21 gene expression during 
differentiation. DF: differentiation factor, CoR: corepressor, CoA: coactivator 
  46  47 
 
p21 promoter and since its expression is increased during hematopoietic 
differentiation it may have a positive regulatory role in this process. However, 
Miz-1 can act as a repressor of the same promoter when it is cooperating with c-
Myc. This is supported by our data indicating that c-Myc utilizes Miz-1 for 
repression of p21 and it enhances DNA binding activity of Miz-1 in vitro and 
possibly also in vivo. Myc has also been reported to facilitate the transport of Miz-
1 to the nucleus (Peukert et al., 1997). Here we suggest that c-Myc/Miz-1 
functions as a growth/differentiation which resembles the E2F/Rb switch for G1/S 
transition. In our suggested model, Miz-1 in complex with Myc represses p21 and 
thereby promoting cell growth and differentiation. When c-Myc is downregulated 
by differentiation signals, Miz-1 operate together with cofactors and other 
transcription factors to activate transcription of p21, which in turn stimulates 
terminal differentiation. Our model is in agreement with other findings from 
studies concerning Myc/Miz-1 interaction. For instance, p15Ink4b promoter has 
been shown to be regulated by Miz-1 and c-Myc (Seoane et al., 2001). In another 
paper it has been suggested that TGF-β downregulates expression of c-myc and 
release Miz-1 from an inhibitory complex with c-Myc. This allowed an interaction 
between Miz-1 and p300 and thereby activated transcription from the p15Ink4b 
promoter (Staller et al., 2001).  
 
  Miz-1 seems to be a keyplayer for both negative and positive signals which 
regulate the p15 and p21 core promoter. A question that can be asked is how Myc 
transform Miz-1 from an activator to a repressor. In p15 repression it has been 
suggested that c-Myc prevents binding of the coactivator p300 to Miz-1 by 
binding to through its HLH domain to the same surface on Miz-1 as p300 (Staller 
et al., 2001). However, we have found apart from the HLH region, that both Zip 
and MBII are required for c-Myc to be able to repress the p21 promoter. This 
contradicts the results from Staller et al. A possible scenario is that a corepressor is 
recruited to the p21 promoter possibly via MBII as shown in our model. 
Interestingly, in a recent paper, it has been shown that Myc recruits a DNA 
methyltransferase corepressor, Dnmt3a, to the p21
Cip1 promoter and thus leading to 
mehtylation and gene silencing (Brenner et al., 2005). c-Myc, Miz-1 and Dnmt3a 
form a ternary complex to repress the promoter. These results are therefore in 
good agreement with our proposed model.  
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Conclusions 
1   The  expression  of  Mad1  is  upregulated  while  c-Myc  is  downregulated           
  during TPA-induced neuronal differentiation of human SH-SY5Y 
neuroblastoma cells.  
 
2   Combined treatment with IFN-γ and RA or TPA has synergistic or enhancing 
effects on morphological differentiation, neurite outgrowth and growth arrest in 
human neuroblastoma cell lines, in particular in those cell lines with amplified N-
myc. 
 
3   IFN-γ -induced terminal differentiation of N-myc-amplified neuroblastoma 
cells involves downregulation of N-Myc and/or upregulation of Mad1 expression 
resulting in reduced N-Myc/Max heterodimerisation, shift in the occupancy of the 
ODC target promoter in vivo from N-Myc/Max towards Mad1/Max and repression 
of N-Myc/Mad1 target genes. 
 
4   Enforced expression of Mad1 in human U-937 monoblasts inhibits cell growth 
and proliferation but does not promote differentiation or survival in general. 
 
5   Differentiation-induced p21Cip1 expression is repressed by Myc in a Miz-1 
dependent manner, correlating with inhibited differentiation. c-Myc binds to the 
p21Cip1 core promoter in vivo through interaction with Miz-1, and seems to 
switch Miz-1 function at the promoter from an activator to a repressor.  
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